Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  28-Aug-2020A Clinical Trial to Study the Effect of a Single Dose of Islatravir 
(MK-8591) on the Pharmacokinetics of Methadone
PRODUCT: MK-8591  1
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Title Page
THIS PROTOCOL AND ALL OF THE INFORMATION RELATING TO IT ARE 
CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK SHARP & 
DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. (MSD).
Protocol Title: A Clinical Trial to Study  the Effect of a Single Dose of Islatravir (MK -8591) 
on the Pharmacokinetics of Methadone
Protocol Number: 029-00
Compound Number: MK-8591
Sponsor Name:
[CONTACT_19519] & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE]- 0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND 128,595
Approval Date: [ADDRESS_632023]: MK-8591  2
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide b y all pr ovisions of this protocol.
Typed Name:
[CONTACT_1641]:Date 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  3
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632024]: MK-8591  4
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
1 PROTOCOL SUMMARY ............................................................................................ 11
1.1 Synopsis ................................................................................................................. 11
1.2 Schema .................................................................................................................. 15
1.3 Schedule of Activities ........................................................................................... 16
2 INTRODUCTION .......................................................................................................... 24
2.1 Study Rationale ....................................................................................................24
2.2 Background .......................................................................................................... 25
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 25
2.2.2 Clinical Studies ............................................................................................ 26
2.2.3 Ongoing Clinical Studies ............................................................................. 26
2.2.4 Information on Other Study -related Therap y.............................................. 26
2.3 Benefit/Risk Assessment ...................................................................................... 27
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 28
4 STUDY DESIGN ............................................................................................................ 30
4.1 Overall Design ......................................................................................................30
4.2 Scientific Rationale for Study Design ................................................................ .31
4.2.1 Rationale for Endpoi nts............................................................................... 32
[IP_ADDRESS] Efficacy  Endpoints ............................................................................. 32
[IP_ADDRESS] Safety  Endpoints ................................................................................ 32
[IP_ADDRESS] Pharmacokinetic Endpoints ............................................................... 32
[IP_ADDRESS] Pharmacod ynamic Endpoints............................................................. 33
[IP_ADDRESS] Planned Exploratory  Biomarker Research .........................................33
[IP_ADDRESS].1 Planned Ge netic Anal ysis........................................................ 33
[IP_ADDRESS] Future Biomedical Research .............................................................. 34
4.3 Justification for Dose ........................................................................................... 34
4.4 Beginning and End of Study Definition ............................................................. 34
4.4.1 Clinical Criteria for Early Study Termination ............................................. 35
5 STUDY POPULATION ................................................................................................ 35
5.1 Inclusion Criteria ................................................................................................ .35
5.2 Exclusion Criteria ................................................................................................ 37
5.3 Lifestyle Considerations ...................................................................................... 39
5.3.1 Meals and Dietary Restrictions ....................................................................39
[IP_ADDRESS] Diet Restrictions................................................................................. 39
[IP_ADDRESS] Fruit Juice Restrictions ......................................................................[ADDRESS_632025]: MK-8591  5
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
5.3.2 Caffeine, Alcohol, and Tobacco Restrictions .............................................. 40
[IP_ADDRESS] Caffeine Restrictions .......................................................................... 40
[IP_ADDRESS] Alcohol Restrictions ........................................................................... 40
[IP_ADDRESS] Tobacco Restrictions .......................................................................... 40
5.3.3 Activity  Restrictions .................................................................................... 40
5.4 Screen Failures .....................................................................................................40
5.5 Participant Replacement Strategy ......................................................................41
6 STUDY INTERVENTION ............................................................................................ 41
6.1 Study Intervention(s) Administered ...................................................................41
6.2 Preparation/Handling/Storage/Accountability ................................................. 43
6.2.1 Dose Preparation .......................................................................................... 43
6.2.2 Handling, Storage, and Accountability ........................................................ 43
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_632026] to Follow -up................................................................................................ .46
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 47
8.1 Administrative and General Procedures ........................................................... 48
8.1.1 Informed Consent ......................................................................................... 48
[IP_ADDRESS] General Informed Consent ................................................................ .48
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 48
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_632027]: MK-8591  6
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
[IP_ADDRESS] Prior Medications ............................................................................... 49
[IP_ADDRESS] Concomitant Medications ..................................................................49
8.1.6 Assignment o f Screening Number ............................................................... 49
8.1.7 Assignment of Treatment/Randomization Number .....................................49
8.1.8 Study  Intervention Administration .............................................................. 50
[IP_ADDRESS] Timing of Dose Administration ......................................................... 50
8.1.9 Discontinuation and Withdrawal ................................................................ .50
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 51
8.1.10 Participant Blinding/Unblinding ..................................................................51
8.1.11 Domiciling ...................................................................................................51
8.1.12 Calibration of Equipment ............................................................................. 51
8.2 Efficacy/Immunogenicity Assessments .............................................................. 51
8.3 Safety Assessments ............................................................................................... 52
8.3.1 Physical Examinations ................................................................................. 52
8.3.2 Vital Signs....................................................................................................52
[IP_ADDRESS] Resting Vital Signs ............................................................................ 52
8.3.3 Electrocardiograms ...................................................................................... 53
8.3.4 Clinical Opi[INVESTIGATOR_2433] (COWS) ................................................ 54
8.3.5 Clinical Safety  Laboratory Assessments ..................................................... 55
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 55
8.4.1 Time Period and Frequency  for Collecting AE, SAE, and Other 
Reportable Safet y Event Information .......................................................... 56
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safet y Events ......57
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety  Event Information ...57
8.4.4 Regulatory  Reporting Requirements for SAE ............................................. 58
8.4.5 Pregnancy  and Exposure During Breastfeeding .......................................... 58
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualify ing 
as AEs or SAEs ............................................................................................ [ADDRESS_632028]: MK-8591  7
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.10.1 Screening...................................................................................................... 60
8.10.2 Treatment Period .......................................................................................... 60
8.10.3 Discontinued Participants Continuing to be Monitored in the Study .......... 60
8.10.4 Poststudy ......................................................................................................60
8.10.5 Critical Procedures Based on Study  Objectives: Timing of Procedure .......61
8.10.6 Study  Design/Dosing/Procedures Modifications Permitted Within 
Protocol Parameters ..................................................................................... 62
9 STATISTICAL ANALYSIS PLAN ............................................................................. 63
9.1 Statistical Analysis Plan Summary.....................................................................63
9.2 Responsibility for Analyses ................................................................................. 65
9.3 Hypotheses/Estimation ........................................................................................ 65
9.4 Analysis Endpoints ............................................................................................... 66
9.5 Analysis Populations ............................................................................................ 66
9.6 Statistical Methods ............................................................................................... 67
9.7 Interim Analyses ..................................................................................................69
9.8 Multiplicity ........................................................................................................... 69
9.9 Sample Size and Power Calculations ................................................................ .69
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS .....................................................................................................71
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_632029] f or Clinical Trials ............................................................. 71
10.1.2 Financial Disclosure ..................................................................................... 73
10.1.3 Data Protection ............................................................................................. 73
[IP_ADDRESS] Confidentiality  of Data ......................................................................74
[IP_ADDRESS] Confidentiali ty of Participant Records ............................................... 74
[IP_ADDRESS] Confidentiality  of IRB/IEC I nformation ............................................ 74
10.1.4 Publication Policy ........................................................................................ 75
10.1.5 Compliance with Study  Registration and Results Posting Requirements ...75
10.1.6 Compliance with Law, Audit, and Debarment ............................................ 75
10.1.7 Data Qualit y Assurance ............................................................................... 76
10.1.8 Source Documents ....................................................................................... 77
10.1.9 Study  and Site Closure ................................................................................. 77
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 78
10.3 Appendix 3: Adverse Events: Definitions and Proce dures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... [ADDRESS_632030]: MK-8591  8
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.3.4 Recording AE and SAE ............................................................................... 81
10.3.5 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................85
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up.............................................................................................................. 86
10.5 Appendix 5: Contraceptive Guidance ................................................................ 87
10.5.1 Definitions ....................................................................................................87
10.5.2 Contraception Requirements ........................................................................89
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research ............................................................................................ 90
10.7 Appendix 7: Country -specific Requirements .................................................... 95
10.8 Appendix 8: Blood Volume Table ......................................................................96
10.9 Appendix 9: 12- Lead Electrocardiogram Abnormality Criteria .................... 97
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values .....99
10.11 Appendix 11: Abbreviations ............................................................................. [ADDRESS_632031]: MK-8591  9
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632032]: MK-8591  10
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632033]: MK-8591  11
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Clinical Trial to Study  the Effect of a Single Dose of Islatravir (MK -8591) 
on the Pharmacokinetics of Methadone
Short Title: Islatravir and Methadone Drug Drug Interaction
Acronym:
Hypotheses, Objectives ,and Endpoints :
Primary  Objectives Primary  Endpoints
-To determine the effect of I SL on the 
plasma pharmacokinetics of methadone (eg, 
AUC0 -24 for S -and R -enantiomers of 
methadone) following  co- administration of 
a single dose of methadone.  
Primary  Hypothesis:  The methadone (R -
enantiomer) plasma AUC0- 24 obtained 
after single dose co- administration of 
methadone with I SL is similar to the 
methadone (R- enantiomer) plasma AUC0-
24 obtained after single dose administration 
of methadone alone. That is, the true GMR 
(methadone and ISL/methadone alone) for 
the dos e-normalized AUC0 -24 (AUC0 -
24/D) of methadone (R -enantiomer) is 
contained within (0.7, 1.43).
Primary  Hypothesis: The methadone (S -
enantiomer) plasma AUC0- 24 obtained 
after single dose co- administration of 
methadone with I SL is similar to the 
methadone (S- enantiomer) plasma AUC0-
24 obtained after single dose administration 
of methadone alone. That is, the true GMR 
(methadone and ISL/methadone alone) for 
the dose -normalized AUC0 -24 (AUC0 -
24/D) of methadone (S -enantiomer) is less 
than 2.0.-Dose -normalized AUC0 -24 (AUC0 -24/D) 
of plasma methadone (R -, and S-
methadone). 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  12
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632034] of I SL on the 
plasma pharmacokinetics of methadone (eg, 
Cmax, C24, and Tmax for the S -and R -
enantiomers and  AU C0-24, Cmax, C24, 
and Tmax for total methadone) following 
co-administration of methadone.
Secondary  Hypothesis: The methadone (R -
enantiomer) plasma Cmax obtained after 
single dose co -administration of methadone 
with I SL is similar to the methadone (R -
enant iomer) plasma Cmax obtained after 
single dose administration of methadone 
alone. That is, the true GMR (methadone 
and I SL/methadone alone) for the dose -
normalized Cmax (Cmax/D) of methadone 
(R-enantiomer) is less than 1.43.
Secondary  Hypothesis: The methadone (S -
enantiomer) plasma Cmax obtained after 
single dose co -administration of methadone 
with I SL is similar to the methadone (S -
enantiomer) plasma Cmax obtained after 
single dose administration of methadone 
alone. That is, the true GMR (methadone 
and I SL/methadone alone) for the dose -
normalized Cmax (Cmax/D) of methadone 
(S-enantiomer) is less than 2.0.
Estimation: The true GMR (methadone and 
ISL/ methadone alone) for the dose 
normalized C24 (C24/D) of methadone (R -
enantiomer and S- enantiomer) will be 
estimated.
Estimation: The true GMR (methadone and 
ISL/methadone alone) for the dose 
normalized AUC0- 24 (AUC0- 24/D), Cmax 
(Cmax/D) and C24 (C24/D) of methadone 
(total) will be estimated.-Dose -normalized Cmax (Cmax/D), C24 
(C24/D), and Tmax of plasma methadone 
(R-, and S- enantiomer).
-Dose -normalized AUC0 -24 (AUC0 -24/D), 
Cmax (Cmax/D), C24 (C24/D), and Tmax 
of plasma methadone (total).
-To evaluate the safet y and tolerability of 
ISL co-administered with methadone.-Adverse experiences, laboratory  safet y 
tests, ECGs, VSs (HR, BP, RR, ox ygen 
saturation). 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  13
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Tertiary /Exploratory  Objectives Tertiary /Exploratory  Endpoints
-To determine the effect of methadone on 
the PK of coadministered I SL-AUC0 -24, AUC0 -168, AUC0- 672, 
AUC0 -inf, Cmax, Tmax, t1/2 of plasma I SL
-To explore the relationship between 
genetic variation and response to the 
treatment(s) administered and mechanisms 
of disease. Variation across the human 
genome may  be anal yzed for association 
with clinical data collected in this study . -Germline genetic variation and association 
to clinical data collected in this study
Overall Desig n:
Study  Phase Phase [ADDRESS_632035] participant’s last 
study -related telephone call or visit.
Number of Participant s:
Approximately  14participants will be allocated/randomized. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  14
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Intervention Groups and Du ration :
Intervention 
Group s
Intervention 
Group Name [CONTACT_210648]-
trationRegimen/ 
Treat ment 
Period /
Regimen Use
Methadone 
MaintenanceMethadone20 –200 
mgQD Oral20 to 200 
mg from 
Day -14 to 
Day -1and 
Day 10 to 
Day 15Back -
ground 
Therapy
Study 
Intervention 
(Islatravir
60mg, 
Individualized 
methadone)ISL 30 mg Once Oral2x 30 mg 
capsules on 
Day 2 Experim
ental
Methadone20 –200 
mgQD Oral20 to 200 
mg from 
Day 1 to 
Day 9Experim
ental
Abbreviations: QD=Once Daily
Other current or former name(s) or alias(es) for study  intervention(s) are as 
follows: ISL, MK -8591, EFdA
Total 
Number of 
Intervention 
Groups/ 
Arms1
Duration of 
ParticipationEach participant will participate in the study  for approximately  [ADDRESS_632036].
Study Governance Committees:
Steering Committee No
Executive Oversight Committee No
Data Monitoring Committee No
Clinical Adjudication Committee No
Study  governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations used in this document can be found in Appendix 11. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  15
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632037]: MK-8591  16
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
1.3 Schedule of Activities
Screening –Day 1
Screening Run-In Intervention Notes
Scheduled Day Screening Day -
14 to 
Day   -
2Day-1 Day 1
Scheduled HourPre-
dose0 0.5 11.5 2 3 4 6 12 16 24
Administrative/Study
Procedures
Informed Consent XThe informed consent form 
must be signed prior to any 
protocol procedures being 
performed .
Informed Consent for Future 
Biomedical ResearchX
Participant Identification Card X
Inclusion/Exclusion Criteria X XInclusion/Exclusion criteria
review maybegin on Day -
1. Eligibility to be 
confirmed after completion 
of all predose assessments. 
Medical History X
Prior/Concomitant Medication 
Revie w  X-------------------------------------------------------------------------------------------------------- -X
Assignment of 
Treatment/Randomization 
NumberX
Methadone Maintenance 
PhaseX---------------- XParticipants will receive 
their standard methadone 
therapy from their usual 
clinic during a minimum
14-day run -in phase ending 
on Day -1. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  17
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Screening –Day [ADDRESS_632038] 
meals will be served per 
site processes beginning ~[ADDRESS_632039] -dose until 8 hrs 
prior to Day 2 dosing.
Dom iciling X---------------------------------------------------------------------------------- XParticipants will check -in 
on Day -1.
Safety Procedures
Full physical examination X
Height X
Weight XNote: BMI to be calculated
only at screening 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  18
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Screening –Day 1
Screening Run-In Intervention Notes
Scheduled Day Screening Day -
14 to 
Day   -
2Day-1 Day 1
Scheduled HourPre-
dose0 0.5 11.5 2 3 4 6 12 16 24
Vital Signs ( heart rate, blood 
pressure, respi[INVESTIGATOR_697], 
oxygen saturation)X X X XParticipants should be 
resting in a semi -recum bent 
position for at least 10 mins 
prior to measurement. 
Respi[INVESTIGATOR_696] r ate and 
oxygen saturation will be 
measured as per SOPs. 
Predose VSshould be 
measured w ithin 3hours of 
methadone dosing.
Vital Signs (temperature) X XPredose VSshould be 
measured w ithin 3hours of 
methadone dosing.
12-lead ECG X X X XParticipan ts should be 
resting in a semi -recum bent 
position for at least 10 mins 
prior to measurement. 
Screening and p re-dose 
ECG sshould be performed 
in triplicate, 1 to 2 minutes 
apart . Predose ECGs should 
be measured within 3hours 
of methadone dosing.
Serum hCG X XPerformed for w omen of 
childbearing potential.
Serum FSH XPerformed for 
postm enopausal women.
Hepatitis B and C screen (per 
site SOP)X 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  19
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Screening –Day 1
Screening Run-In Intervention Notes
Scheduled Day Screening Day -
14 to 
Day   -
2Day-1 Day 1
Scheduled HourPre-
dose0 0.5 11.5 2 3 4 6 12 16 24
HIV antigen/ antibody screen XParticipants must have 
negative HIV 
antigen/ antibody test at 
screening.
STI Urine screen XInclude stesting for 
gonorrhea, chlamydia, and 
trichomoniasis at minimum.
Syphilis serologic screening X
UDS (per site SOP) X XScreening and Day -1UDS
is mandatory, any 
additional UDS are 
conducted per site SOP.
Hem atology , Urinalysis, 
ChemistryX XCollected after at least an [ADDRESS_632040] at screening and 
predose .
AE/SAE review X----------------------------------------------------------------------------------------------------------- X 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  20
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Screening –Day [ADDRESS_632041]: MK-8591  21
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Day 2 –Post-study
InterventionFollow -
Up CallNotes
Scheduled Day Day 2 Day 3Day 4Day 
5Day 
6Day 
9Day 
10 
to 
Day 
15Day 16a
Scheduled Hour 00.25 0.5 11.5 234 6 12 16 24 48 72 96 168
Administrative/Study
Procedures
Prior/Concomitant 
Medication ReviewX---------------------------------------------------------------------------------------------------------------------- X
Methadone 
Maintenance TherapyXAfter the follow -up call on 
~Day 16, methadone 
maintenance therapy will 
continue as per the 
participant ’s standard 
schedule . 
Methadone 
AdministrationX X X------------------------ XOn Day 2, participants will 
receive a maintenance dose 
of methadone after an 
overnight fast of at least 8 
hours with ~[ADDRESS_632042] for 4 hours 
postdose. From Day 3 (ie, 
Day 2, 24 hrs) to Day 9 (ie, 
Day 2, 168hrs), participants 
will receive methadone 
once daily at the clinic . 
Islatravir 
AdministrationXOn Day 2, participants will 
receive a dose of ISL within 
5 minutes of the methadone 
dose with ~[ADDRESS_632043]: MK-8591  22
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Day 2 –Post-study
InterventionFollow -
Up CallNotes
Scheduled Day Day [ADDRESS_632044] -dose until
discharge from the clinic on 
Day 9.
Dom iciling X--------------------------------------------------------------------------------------------------- X
Safety Procedures
Full physical 
examinationX
Weight X
Vital Signs ( heart rate, 
respi[INVESTIGATOR_697], oxygen 
saturation)X X X X XParticipants should be 
resting in a semi -recum bent 
position for at least [ADDRESS_632045] 
operating procedures.
Predose VSon Day 2 
should be measured w ithin 
3hours of methadone 
dosing.
Vital Signs 
(temperature )X 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  23
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Day 2 –Post-study
InterventionFollow -
Up CallNotes
Scheduled Day Day [ADDRESS_632046] . Collected prior to 
methadone dosing .
AE/SAE review X--------------------------------------------------------------------------------------------------------------------- X
Pharm acokinetics
Blood for Plasma ISL
X X X X X X X X X X X X X0 h sample to be collected 
just prior to ISL 
administration.
Blood for Methadone XXXXXX X X X X
aFollow -up call will occur 14 days (+3 days) after the ISL dose.
bA total of [ADDRESS_632047]:   MK-8591  24
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
2 INTRODUCTION
Islatravir (MK -8591, ISL) is a novel, potent NRTTI  being developed both for treatment of 
HIV-1 infection and for prevention of HIV- 1 infection in uninfected individuals at high risk
of becoming infected.  Currentl y, IS L is being evaluated in a Phase 2 trial at a dose of 0.75 
mg QD (in combination with 100 mg doravirine, DOR; [STUDY_ID_REMOVED]) and in a Phase 2 trial 
at doses of 60 mg and 120 mg QM ( [STUDY_ID_REMOVED] ). Additional programs with other doses 
and administration frequencies within the range of 0.[ADDRESS_632048] declined, but injecting drugs remains 
a significant risk factor in becoming infected with HIV . In 201 8, 7% (2,652 ) of the estimated 
37,881new HIV infections in the [LOCATION_002] were attributed to IDU [Centers for Disease 
Control and Prevention 2020] . Many PWIDseek treatment for opi[INVESTIGATOR_491468] y with the opi[INVESTIGATOR_491469]. 
Consequently , individuals on M MT may  benefit from I SL either for treatment of existing 
HIV infection or proph ylacticall y to prevent new infection. Success of M MT is sensitive to 
many  factors and complicated b y inter -subject variability in both methadone PK and PD . 
Titration of methadone dosing is necessary  to balance the reduction of craving for opi[INVESTIGATOR_858] , 
the medical necessity  of avoiding opi[INVESTIGATOR_2533] , and the effects associated with 
methadone toxicity . 
Methadone has been shown to be metabolized by [CONTACT_491485] P450 
family  including CYP3A4, 2B6, 2C19, 2D6, 2C9 and 2C8, with CYP3A4 usually  cited as the 
most active member when using human microsomes in vitro[Volpe, D. A., et al 2018] [Eap, 
C. B., et al 2002] . Interactions between HIV antiretrovirals and methadone have been widel y 
reported , with methadone being affected b y both induction and inhibition of metabolic 
enzy mes b y antiretrovirals. Generally, the interaction s found to be clinicall y meaningful were 
due to decreases in methadone exposure [Volpe, D. A., et al 2018] [Eap, C. B., et al 2002] .
ISL is not anticipated to be a perp etrator of meaningful drug interactions. ISL is not an 
inhibitor of major CYP enzy mes(eg, CYP 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 ) or inducer 
of CYP2B6 or CYP3A4 .
There are reports of methadone affecting the pharmacokinetics of coadministered HIV 
antiretrovi rals. Methadone decreases exposure of didanosine and stavudine (older HIV 
antiretrovirals), possibl y due to delay ed gastric empty ing[Rainey , P. M., et al 2000] . In 
addition, there are reports of increased zidovudine exposure mediated through inhibition of 
glucuronidation or altered renal clearance [McCance -Katz, E. F., et al 1998] [Schwartz, E. L ., 
et al 1992] [Volpe, D. A., et al 2018] .Methadone is also an inhibitor of P -glycoprotein (P -
gp). ISL is highl y soluble and rapi[INVESTIGATOR_2478] y absorbed, is not metabolized via glucuronidation and is 
not a substrate of P -gp. Therefore, it is unlikely  that methadone will affect the PK of I SL.
The concomitant use of ART to treat or prevent HIV -1 with MMT may  interfere with the 
efficacy /safet y of ART and/or with the ability to maintain stable methadone concentrations 
leading to s ymptoms of either opi[INVESTIGATOR_491470] -
threa tening consequences. While no interaction is expected, given the importance of ensuring  
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  25
PROTOCOL/AMENDMENT N O.:  [ADDRESS_632049] of I SL 
administration on methadone PK . Additionally , ISL PK in the presence of meth adone will be 
evaluated.
2.2 Background
Refer to the IB/approved labeling for detailed background information on islatravir (ISL or 
MK-8591) .
HIV-1 infection remains a global health challenge, with 3 8million people living with 
HIV/AIDS worldwide and nearl y 2million people becoming newl y infected[Joint United 
Nations Programme on HIV/AIDS 2020] . The use of ever -improving highly  effective AR T
has reformed the natural history  of HIV infection, such that HIV infection has become a 
chronic illness ,provided patients remain adherent in taking ART therapy .Furthermore, use 
of ART as pre- exposure prophy laxis to prevent new HIV infection ( eg,PrEP) has been 
shown to reduce sexual transmission by [CONTACT_8622] 99% and transmission i n intravenous drug 
users b y up to 74% [Centers for Disease Control and Prevention 2020] . Islatravir is a n NRTTI 
in development as a part of a complete ART regimen for the treatment of HIV -[ADDRESS_632050] indicated 
for treatment of moderate to severe pain and/or opi[INVESTIGATOR_9827]. 
2.2.1 Pharmaceutical and Th erapeutic Background
Islatravir is a highl y potent HIV -1NRT TI.Unlike conventional NRTIs, ISL actsvia multiple 
mechanisms, leading to both immediate and delayed chain termination. The inactive parent is 
phosphory lated to the active ISL-TP in PBMCs and ot her cells. In in vitro studies inPBMCs, 
ISL-TP demonstrated antiviral activity , with an IC 50of 0.21 nM, while other NRTIs 
demonstrated IC 50s ranging from 10.1 to 144 nM. IS Ldemonstrates a favorable mutant 
selection profile compared to other NRTIs ,selecting onl y for the M184V/I mutant, against 
which I SLis active but with a decrease in sensitivity  of 7.[ADDRESS_632051] . ISL is not a substrate of 
P-gp. ISL is not an inhibitor of major drug transporters, inhibitor of CYP enzy mes(eg, 
CYP 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4 ), inducer of CYP2B6 or CYP3A4, or an inhibitor 
of UGT1A1 . 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  26
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
2.2.2 Clinical Studies
Across Phase 1 studies, as of 30-Jun-2020, 218 adult participants (including 30 participants 
with HIV-1 infection ) received a nISLsingle dose (up to 400 mg orally) or multiple doses 
(up to 100 mg QW for 3 weeks and up to 5 mg QD for 6 weeks orally).  In the Phase [ADDRESS_632052] frequently  reported drug -related AE ( ≥2% of participa nts in an y 
protocol) was headache. 
Following oral administration, p lasma PK data indicate that ISLwas rapi[INVESTIGATOR_63946] a 
median Tmax of 0.5 hr, and an apparent terminal t½ of 47 to 64 hr after single doses. 
Intracellular ISL-TP levels reached C maxbetween 6 to 24 hr and declined with an apparent 
terminal t½ of 79 to 214 hr. Over the entire Phase 1 clinical program, ISL plasma exposure 
and I SL-TP levels appeared to increase in an approximately  dose -proportional manner 
between ISL doses of 0.25 and 400 mg. Following administration of 30 mg ISL with a high -
fat meal, PK of ISL and ISL-TP in PBMCs were largel y unaffected. Examinations of DDIs 
between ISLand DTG/TDF, ISLand LNG/EE, ISLand DOR, and ISL and pantoprazole 
demonstrated no clinically  meaningfu linteractions.
After ISL administ ration to treatment -naïve participants with HIV- 1 infection at doses of 0.5 
mg, 1 mg, 2 mg, 10 mg ,and 30 mg , viral load reduction data show greater than 1.0 log drop 
on average at all doses tested .Pharmacokinetic data i n participants infected with HIV-1 
generall y were consistent with the data in health y participants.
2.2.3 Ongoing Clinical Studies
There are ten ongoing studies of oral ISL , including 4 Phase 1 trials, 2 Phase 2 trials and 4 
Phase 3 trials. To date, the I SL remains generall y well tolerated. 
Protocol 011 ( [STUDY_ID_REMOVED]) is an ongoing Phase 2 trial in treatment -naive persons living 
with HIV- 1, examining efficacy  of dail y ISL (0.25 mg, 0.75 mg, or 2.25 mg) in combination 
with DOR . As of 31 -Mar-2020, ISL has been administered to ~[ADDRESS_632053] 96 weeks. Protocol 016 (P016) is a double -blind, placebo- controlled Phase 2 PrEP
trial([STUDY_ID_REMOVED]), examining doses of 60 mg and 120 mg. As of 30- June-2020, 156 of a 
planned 250 participants (62%) have been randomized and [ADDRESS_632054] received between 3 -5 doses; the 
remaining [ADDRESS_632055] r eceived fewer than 3 doses.
The 4 Phase 3 trials initiated in earl y 2020; information on general tolerability is limited.
2.2.[ADDRESS_632056] indicated for the management of pain for which alternative 
treatment options are inadequate and for the detoxification treatment of opi[INVESTIGATOR_9827] . 
Together with appropriate social and medical services, methadone is also used as MMT for 
the treatment of opi[INVESTIGATOR_9827] [U.S. Prescribing Information 2019] . 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  27
PROTOCOL/AMENDMENT N O.:  [ADDRESS_632057] prominent of which 
involve the central nervous system and organs composed of smooth muscl e [U.S. Prescribing 
Information 2019] .Methadone is supplied and administered clinically  as a racemate of R-
and S -enantiomers, though the R- enantiomer accounts for the majority  ofits 
pharma cological activity . Due to high intersubject variability  both in PK and
pharmacological response, methadone dose must be individual lytitrated[Volpe, D. A., et al 
2018] [Eap, C. B., et al 2002] .
Following oral administration, the bioavailability  of methadone ranges between 36 to 100% 
and peak plasma concentrations are achieved between 1 to 7.5 hours. While d ose 
proportionality  of methadone PKhasnot been definitively  established, after administration of 
daily  oral doses ranging from 10 to 225 mg, the stead y-state plasma concentrations ranged 
from 65 to 630 ng/mL and the peak concentrations ranged between 124 to 1255 ng/mL.
These data suggest that generall y, PK of methadone increases dose proportionall y [U.S. 
Prescribing Information 2019] .Published reports indicate that after multiple dose 
administration the apparent plasma clearance of methadone ranged between 1.4 and 126 L /h, 
and the terminal half -life was highl y variable and ranged between 8 to 59 hours in different 
studies [U.S. Prescribing Information 2019] .
2.3 Benefit/Risk Asse ssment
Participants in clinical studies will not receive direct benefit from treatment during 
participation as clinical studies are designed to provide information about the safet y and 
effectiveness of an investigational medicine.
The data generated will be used to support coadm inistration of I SL and methadone. Patients 
taking methadone have a high rate of HIV -infection or are at elevated risk for acquiring new 
HIV infection. Therefore, I SL may  be an important therap y for HIV treatment or prevention 
in this population.
Additional details regarding specific benefits and risks for participants taking part in this 
clinical study  may  be found in the accompan ying IB and informed consent documents. 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  28
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
The study  population includes male and female par ticipants from18 years to 65 y ears of age, 
inclusive .
Objectives Endpoints
Primary
•To determine the effect of ISLon the 
plasma pharmacokinetics of methadone
(eg, AUC0 -24for R-and S-enantiomers
of metha done) following co-
administ ration of a single dose of 
methadone .
Primary  Hypothesis: The methadone 
(R-enantiomer) plasma AUC0- 24 
obtained after single dose co-
administration of methadone with I SL is 
similar to the methadone (R -enantiomer) 
plasma AUC0- 24 obtained after single
dose administration of methadone alone.
That is, the true GMR (methadone and 
ISL/methadone alone) for the dose -
normalized AUC0- 24 (AUC0 -24/D) of 
methadone (R- enantiomer) is contained 
within (0.7, 1.43 ).
Primary  Hypothesis: The methadone (S -
enantiomer) plasma AUC0- 24 obtained 
after single dose co- administration of 
methadone with I SL is similar to the 
methadone (S- enantiomer) plasma 
AUC0 -24 obtained after single dose 
administration of methadone alone. That 
is, the true GMR (methadone and 
ISL/methadone alone) for the dose -
normalized AUC0- 24 (AUC0-24/D) of 
methadone ( S-enantiomer) is less than 
2.0.•Dose -normalized AUC0 -24 (AUC0 -
24/D) of plasma methadone (R -and S -
methadone). 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  29
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Objectives Endpoints
Secondary
•To determine the effect of ISLon the 
plasma pharmacokinetics of methadone 
(eg,Cmax , C24, and Tmax for the R-
and S-enantiomers and A UC0-24, 
Cmax , C24, and Tmax for total 
methadone ) following co -administ ration 
of methadone .
Secondary  Hypothesis: The methadone 
(R-enantiomer) plasma Cmax obtained 
after single dose co- administration of 
methadone with I SL is similar to the 
methadone (R- enantiomer) plasma 
Cmax obtained after single dose 
administration of methadone alone. That 
is, the true GMR (methadone and 
ISL/methadone alone) for the dose -
normalized Cmax (Cmax /D) of 
methadone (R- enantiomer) is less than 
1.43.
Secondary  Hypothesis: The methadone 
(S-enantiomer) plasma Cmax obtained 
after single dose co- administration of 
methadone with I SL is similar to the 
methadone (S- enantiomer) plasma Cmax 
obtained after single dose administration 
of methadone alone. That is, the true 
GMR (methadone and ISL/methadone 
alone) for the dose -normalized Cmax
(Cmax /D) of methadone ( S-enantiomer) 
is less than 2.0 .
Estimation: The trueGMR (methadone 
and ISL/ methadone alone) for the dose 
normalized C24 (C24/D) of methadone 
(R-enantiomer and S -enantiomer ) will 
be estimated.
Estimation: The trueGMR (methadone 
and ISL/methadone alone) for the dose 
normalized AUC0- 24 (AUC0- 24/D), 
Cmax (Cmax/D) and C24 (C24/D) of 
methadone (total) will be estimated.•Dose -normalized Cmax (Cmax/D), C24 
(C24/D), and Tmax of plasma 
methadone (R- and S -enantiomer ).
•Dose -normalized AUC0 -24 (AUC0 -
24/D), Cmax (Cmax/D), C24 (C24/D), 
and Tmax of plasma methadone (total). 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  30
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Objectives Endpoints
•To evaluate the safet y and tolerability  of 
ISLco-administered with methadone.•Adverse experiences, laboratory  safet y 
tests, ECGs, VS s(HR, BP, RR, ox ygen 
saturation).
Tertiary /Exploratory
•To determine the effect of methadone on 
the PK of coadministered I SL.•AUC0 -24, AUC0 -168, AUC0- 672, 
AUC0 -inf, Cmax, Tmax, t1/2 of plasma 
ISL
•To explore the relationship between 
genetic variation and response to the 
treatment(s) administered and 
mechanisms of disease . Variation across 
the human genome may  be anal yzed for 
association with clinical data collected in 
this study . •Germline genetic variation and 
association to clinical data collected in 
this study
[ADDRESS_632058]:   MK-8591  31
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Because this is a Phase 1 assessment of ISLin humans, the PK, pharmacody namic, and 
safet y profiles of the compound are still being elucidated. This protocol is therefore written 
with flexibility  to accommodate the inherent d ynamic nature of Pha se 1 clinical studies. 
Refer to Section 8.11.6 for examples of modifications permitted within the protocol 
parameters.
Specific procedures to be performed during the stud y, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
4.2 Scientific Rationale for Study Design
This study  will evaluate the potential drug -drug interaction between methadone and ISL. The 
study  design was chosen to optimally  assess the objectives of the stud y.
A fixed- sequence design was selected for operational efficiency given the half -life of plasma 
ISL and intracellular I SL-TP.
Population: Steady state methadone disposition cannot be evaluated safel y in participants
not on methadone for the duration specified in this trial without a substantial risk of causing 
methadone addiction. Participants without HI V infection will be enrolled to avoid 
interactions between ISL and other ART or to avoid exposing HIV infected individuals not 
on ART to HIV monotherap y.Participants will be screened for illicit drug use (except 
cannabis) and STIs as use of injection drugs and presence of STIs may  indicate incre ased risk 
of contracting HIV during the st udy[Centers for Disease Control and Prevention 
2020] [Centers for Disease Control and Prevention 2015] .
Run-in Period: Methadone dose must be individually  titrated and periodically  adjusted to 
maintain optimal therapeutic effect. In addition, methadone has the potential to be both an 
inducer and autoinducer. To ensure that evaluation of a DDI on Day  1 and 2 in this study  is 
done at stead y-state concentrations of methadone and at stead y-state levels of metabolic 
enzy mes, a 14 -day run-in period at a stable methadone dose will proceed the active treatment 
period in this study .
Doses :Methadone doses are individually  titrated. Participants will remain on their stable 
methadone dose. A wide range of doses will be evaluated in this study  (20 to 200 mg). Lower 
doses may  not be clinically  relevant ,while increases in QTc prolongation were observed at 
doses >200 mg [U.S. Prescribing Information 2019] . 
A dose of 60mg ISLhas been selected to be administered as a one -time oral dose in this 
trial. This dose of I SL is the anticipated highest clinical dose being considered for
development , and ISL has demonstrated dose -proportional PK over the entire range studied 
to date (0.25 mg –400 mg) . While no drug interaction between ISL and methadone is 
anticipated, it is desirable to test this hypothesis at the upper end of the clinic ally relevant 
dose range as a lack of effect at this dose could be extrapolated to lower doses. As plasma 
accumulation of ISLis low and no induction or time dependent inhibitory  effect is  
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  32
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
anticipated, a single dose paradigm is considered adequate to asse ss the DDI with 
methadone .
Food :The effect of food on the bioavailability  of methadone has not been evaluated [U.S. 
Prescribing Information 2019] . There is no clinically  relevant effect of food on ISL
pharmaco kinetics . However , dosing on D ays1 & [ADDRESS_632059] is 
completed.
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Efficacy Endpoints
There are no efficacy  endpoints.
[IP_ADDRESS] Safety Endpoints
Participants will be observed at the clinical trial site where they  are housed. Symptoms of 
CNS or respi[INVESTIGATOR_491471] b y staff trained in the management of opi[INVESTIGATOR_491472]/or critical c are. 
Respi[INVESTIGATOR_491473]. A baseline COWS assessment will be done 
at screening and 
prior to dosing on Day  1; in the event that overt signs of opi[INVESTIGATOR_491474] y, additional COWS assessments may be conducted as clinically indicated 
[Wesson, D. R. 2003] . 
In addition, safet y laboratory evaluations (hematology and chemistr y), ECGs and vital signs 
will be conducted to monitor subject safet y throughout the study. Particular attention will be 
paid to the QTc interval of pa rticipants as methadone is known to cause QTc prolongation. 
No effects of ISL on QTc is predicted based on the electroph ysiolog ic studies of ISLin vitro 
and in vivo animal models or clinical trials .
[IP_ADDRESS] Pharmacokinetic Endpoints
To characterize the pharmacokinetics of methadone (R -and S -enantiomers and total) and 
determine if there is a clinically  meaningful change in methadone pharmacokinetics when co -
administered with ISL, AUC0 -24, Cmax , C24 and Tmax will be evaluated on Day 1 (without 
ISLadministration) and on Day  2 (following co -administration with ISL). AUC0- 24 will be 
evaluated since the PK evaluations are under steady -state conditions. 
Methadone is supplied and administered clinically  as a racemic mixture, although only  one 
enantiomer (R -) accounts for the majorit y of its pharmac ological activity .Therefore, lower 
clinical significance bounds are set around PK of the R -enantiomer. The level to which 
methadone concentrations may safel y change in any given patient is complic ated b y high 
interindividual variability in both PK and PD. Literature survey s have shown that mean  
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  33
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
reductions in methadone exposure on the order of ~30% to ~50% are associated with 
withdrawal s ymptoms in at least some individuals (eg, due to interaction w ith efavirenz or 
nevirapi[INVESTIGATOR_050]). Therefore, the lower bound in this study for the R -enantiomer is being set at 0.7. 
While methadone intoxication/toxicity related to on- target pharmacological activity has been 
less widely reported with inhibition , increases i n drug levels are associated with QT 
prolongation. An increase of 47% of the R -enantiomer and 103% of the S -enantiomer in the 
presence of voriconazole are accompanied b y cautionary QT label language [U.S. 
Prescribi ng Information 2019] [Maremmani, I ., et al 2005] [Eap, C. B., et al 2002] .Based on 
this, the upper bound of clinical significance for AUC is set sy mmetricall y at 1.[ADDRESS_632060] closely  associated with intracellular ISL-TP 
concentrations at trough (C168). Because ISL-TP has been shown to correlate closel y with 
plasma I SL AUC which can be more readily  measured, plasma ISL AUC is being assessed as 
a surrogate associated with efficacy . It is also considered the most relevant parameter for 
toxicity . Given the range of dosing frequencies being evaluated in ISL development, AUC0 -
24 (daily ), AUC0- 168 (weekl y), and AUC0 -672 (monthly ) will all be estimated. Itis not 
possible to remove MMT patients from their established dosing regimen without substantial 
risk of inducing wi thdrawal sy mptoms and their attendant psy chological sequelae. As a 
consequence, it is not possible to include an I SLalone treatment period for comparison to the 
methadone + ISL coadministration. Therefore, ISL plasma PK will be evaluated in this study  
with methadone coadministration and compared in an exploratory way  to historical I SL PK 
data.
[IP_ADDRESS] Pharmacodynamic Endpoints
No pharmacod ynamic endpoints will be evaluated.
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].1 Planned Genetic Analysis
Genetic variation may  impac t a participant’s response to therap y, susceptibility  to, severit y, 
and progression of disease. Variable response to therap y ma y be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
thedrug; disease etiology ; and/or molecular subty pe of the disease being treated. Therefore, 
where local regulations and I RB/IEC allow, a sample will be collected for DNA anal ysis 
from consenting participants. 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  34
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
DNA samples may be used for research related to the study  intervention( s), the disease under 
study , orrelated diseases. They  may  also be used to develop tests/assay s including diagnostic 
tests related to the disease under stud y, related diseases, and stud y intervention(s). Genetic 
research may  consist of the anal ysis of 1 or more candidate genes , the analy sis of genetic 
markers throughout the genome , or analy sis of the entire genome. Anal ysis may  be 
conducted if it is hy pothesized that this may  help further understand the clinical data.
The samples may  be analy zed as part of a multi -study  assessment of genetic factors involved 
in the response to understand study  disease or related conditions.
[IP_ADDRESS]      Future Biomedical Research
The Sponsor will conduct FBR on DNA spe cimens for which consent was pr ovided during 
this clinical study .
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective of collecting/retaining specimens for 
FBR is to explore and identify  biomarkers that inform the scientific understanding of 
diseases and/or their therapeutic treatments. The overarching goal is to use such information 
to develop safer, more effective drugs/vaccines, and/or to ensure that participants receive the 
correct dose of the correct drug/vaccine at the correct time. The details of FBR are presented 
inAppendix 6.
4.[ADDRESS_632061] udy objectives and/or to 
ensure appropriate safet y monitoring of the stud y participants. Details of allowed 
modifications are provided in Section 8.11.6.
4.[ADDRESS_632062] to follow -up (ie, the participant is unable to be contact[INVESTIGATOR_530] b y the 
investigator) .
Astudy  may  be paused during review of newl y available preclinical/clinical safet y, PK , 
pharmacod ynamic, efficacy , or biologic data or other items of interest, prior to a final 
decision on continuation or termination of the study. It may  be necessary  to keep the study  
open for gathe ring/reviewing of additional supportive data to optimally  complete the 
objective(s) of the study . If necessary , the appropriate amendment(s) to the protocol and/or 
appropriate communication(s) will be generated. If the decision has been made to end the  
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  35
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
study following this review period, the study  end will be defined as the date of the Sponsor 
decision, and this end of study  date supersedes the definitions outlined above . The 
Competent Authority (ies) and IRB(s)/IEC(s) will be apprised of the maximum duration of 
the study  beyond the last participant out and the justifica tion for keepi[INVESTIGATOR_491475].
4.4.1 Clinical Criteria f orEarly Study Termination
There are no prespecified criteria for terminating the study  early.
5 STUDY POPULATION
Males and females meeting the criteria outlined below will be enrolled.
Prospe ctive approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant will be e ligible for inclusion in the study  if the participant :
Type of Participant and Disease Characteristics
1.Hasa BMI > 18 and ≤ 35 kg/m2. See Section 8.3.1for criteria on rounding to the 
nearest whole number. BMI=weight (kg)/height (m)2.
2.Is in good health based on laboratory  safet y tests obtained at the screening visit and 
prior to administration of study  drug. Appendix 2 provides a table of laboratory  safet y 
tests to be performed. Appendix 10 provides an algorithm for the assessment of ou t of 
range laboratory  values. 
Note: participants infected with Hepatitis C or Hepatitis B may be included if 
Screening and Baseline AL T is <[ADDRESS_632063] bilirubin 
is <2-fold the upper limit of normal. Participants slightly  exceeding these limits may  
be retested and enrolled upon consultation with Sponsor.
3. Is in good health based on medical history , physical examination, VS measurements 
and ECGs performed prior to randomization. Appendix [ADDRESS_632064] rocardiogram Abnormality  Criteria.
4.Hasa negative HIV antigen/ antibody  test at screening .
Demographics
5.Ismale or female , from 18yearsto 65yearsof age ,inclusive, at the time of signing 
the informed consent. 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  36
PROTOCOL/AMENDMENT N O.:  [ADDRESS_632065] one of the following conditions applies : 
•Is not a WOCBP
OR
•Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifesty le (abstinent on a long -term 
and pers istent basis), as described in Appendix [5] during the intervention period and for 
at least [ADDRESS_632066] dose of study  intervention. The investigator should evaluate 
the potential for contraceptive method failure (ie, noncompliance, recentl y initiated) in 
relationship to the first dose of study intervention.
•A WOCBP must have a negative highly  sensitive pregnancy  test (serum) as required b y 
local regulations within [ADDRESS_632067] dose of study intervention.
•Additional requirements for p regnancy  testing during and after stud y intervention are in 
Section 8.3.5.
•The investigator is responsible for review of medical history , menstrual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy .
•Contraceptive use b y women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
Informed Consent
6.The participant provides written informed consent for the stud y. The parti cipant may  
also provide consent for FBR. However, the participant may  participate in the main 
study  without participating in FBR.
Additional Categories
7.Isreliabl y participating in a methadone maintenance program for at least two (2) 
months prior to Day  1. Subjects are required to be on a documented stable dose of 
methadone for at least 14 day s prior to Day  1.
8.Agree sto not change their current maintenance methadone dose of 20 -200 mg 
administered as a single daily  dose (unless for safety  reasons) from screening until  
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  37
PROTOCOL/AMENDMENT N O.:  [ADDRESS_632068] dose of 
study  medication :
a.Use a male or female condom (but not both together) during all occurrences of 
penetrative vaginal or anal intercourse.
b. Avoid coming into contact [CONTACT_491486]’s blood (eg ,by [CONTACT_460747] a 
hypodermic needle ).
5.[ADDRESS_632069] be excluded from the study  if the participant:
Medical Conditions
1.Has a history  of clinically  significant endocrine, gastrointestinal, cardiovascular, 
hematological, hepatic, immunological, renal, respi[INVESTIGATOR_696] , genitourinary , or major 
neurological (including stroke and ch ronic seizures) abnormalities or diseases. 
Participants with a remote history  of uncomplicated medical events (eg, uncomplicated 
kidney  stones, as defined as spontaneous passage and no recurrence in the last 5 y ears, or 
childhood asthma) may  be enrolled in the stud y at the discretion of the investigator.
Exception: Subjects infected with hepatitis B or hepatitis C virus may  participate if they  
meet Inclusion Criteria 2 and 3.
2.Is mentally  or legall y incapacitated, has significant emotional problems at the ti me of 
prestudy  (screening) visit or expected during the conduct of the study  or has a history  of 
clinically  significant ps ychiatric disorder of the last [ADDRESS_632070] had 
situational depression may  be enrolled in the study at the discretio n of the investigator. 
3.Has a history  of cancer (malignancy ).
Exceptions: (1) Adequately  treated nonmelanomatous skin carcinoma or carcinoma in 
situ of the cervix or; (2) Other malignancies which have been successfully  treated with 
appropriate follow up a nd therefore unlikel y to recur for the duration of the study, in the 
opi[INVESTIGATOR_100892] (eg, malignancies which 
have been successfully  treated ≥10 y ears prior to the prestud y [screening] visit).
4.Has a history  of significant multiple and/or severe allergies (eg, food, drug, latex allergy ), 
or has had an anaph ylactic reaction or significant intolerability  (ie, s ystemic allergic 
reaction) to prescription or non- prescription drugs or food. 
  05KTY6
05KTY6
07ZM3G
PRODUCT:   MK-8591  38
PROTOCOL/AMENDMENT N O.:  [ADDRESS_632071] 1 unit of blood (approximately  500 mL) within [ADDRESS_632072] 
history  of syphilis may  be enrolled if, in the opi[INVESTIGATOR_871], clinical evidence 
do not indicate presence of a new infection.
Prior/Concomitant Therapy
7.With the exception of methadone, is unable to refrain from or anticipates the use of an y 
medication, including prescription and non -prescription drugs or herbal reme dies 
beginning approximately 2 weeks (or 5 half -lives) prior to the first dose of the 14 day  
methadone maintenance run-inphase prior to Day 1, throughout the trial, until the AE 
follow -upcall(Day  16). Upon discussion with the Sponsor, concomitant use of 
benzodiazepi[INVESTIGATOR_491476] a stable benzodiazepi[INVESTIGATOR_491477]  a ph ysician for at least [ADDRESS_632073] dose of stud y drug in this t rial.In addition, t here may  
be certain prescription and non- prescription drugs that are permitted, see Section 6.5.
Prior/Concurrent Clinical Study Experience
8.Has participated in another investigational study within 4 weeks (or 5 half -lives) prior to 
the prestud y (screening) visit. The window will be derived from the date of the last visit 
in the previous study .
Diagnostic Assessments
9.Has a QTc interval >450 msec (males) or >470 msec (females) , has a history  of risk 
factors for Torsades de Pointes (eg, heart failure/cardiomy opathy  or famil y history  of 
long QT s yndrome), has uncorrected h ypokalemia or hy pomagnesemia, is taking 
concomitant medications that prolong the QT/QTc interval other than methadone .
Other Exclusions
10.Is under the age of legal consent .
11.Does not limit smoking to no more than [ADDRESS_632074] agree to follow the smoking restrictions defined by [CONTACT_96002] U.
12.Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately  
equivalent to: beer [354 mL /12 ounces], wine [118 mL /4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 
mL/1 ounce]) per day . Participants who consume [ADDRESS_632075]:   MK-8591  39
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
13.Consumes excessive amounts, defined as greater than 6 servings (1 serving is 
approximately  equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or 
other caffeinated beverages per day .
14.With the exception of THC, has a positive screen for drugs with a high potential for 
abuse such as cocaine, amphetamines, MDMA, barbiturates, benzodiazepi[INVESTIGATOR_1651] (with the 
exception not ed in exclusion criteria 7), or opi[INVESTIGATOR_858]/opi[INVESTIGATOR_491478]  -[ADDRESS_632076] a negative UDS prior to randomization, with the except ion of THC 
and prescription benzodiazepi[INVESTIGATOR_1651].
15.Presents an y concern b y the investigator regarding safe participation in the study  or for 
any other reason the investigator considers the participant inappropriate for participation 
in the study .
16.Has a COWS scor e of ≥ 5 at screening or prior to randomization.
17.Is unwilling to comply  with the study  restrictions (see Section 5.3 for a complete 
summary  of study  restrictions) .
18.Is or has an immediate family  member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly  involved with this study .
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
[IP_ADDRESS] Diet Restrictions
Fasting requirements for study  procedures, such as but not limited to laboratory  safet y 
evaluations are specified in Appendix 2.
On full pharmacokinetic sampling day s, ie, Day s [ADDRESS_632077] 
scheduled meal at approximately  4 hours postdose. Otherwise, m eals and snack(s) will be 
provided b y the investigator per site standards during domiciling in the clinic. Participants 
will fast from all food and drinks except water between meals and snacks. The caloric 
content and composition of meals will be the same on Day  [ADDRESS_632078]:   MK-8591  40
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
[IP_ADDRESS] Fruit Juice Restrictions
Participants will refrain from the consumption of grapefruit juice, grapefruits, and grapefruit 
products beginning approximately  [ADDRESS_632079] dose of the 
14day  methadone maintenance run-inphase prior to Day  1until discharge from the clinic on 
Day 9. 
On full pharmacokinetic sampling day s, ie, Day s 1 and 2, participants will refrain from the 
consumption of all fruits and fruit juices 24 hours prior to and 4 hours following trial drug 
administration . On all other day s during the stud y, consumption of fruits and fruit juices 
(except for grapefruit, grapefruit juices, and grapefruit products) is allowed.
5.3.2 Caffeine, Alcohol ,and Tobacco Restrictions
[IP_ADDRESS] Caffeine Restrictions
Participants will refrain from consumption of caffeinated beverages or xanthine -containing 
products from 12 hours prior to the prestud y visit until after the visit , from 12 hours prior to 
and after study  drug administration on Day s 1 and 2, and from 12 hours prior to the Day  9
(ie, 168hr pos t ISL dose) procedures . At all other times, caffeinated beverages or xanthine -
containing products will be limited to no more than 6 units per day  (1 unit = 120 mg of 
caffeine).
[IP_ADDRESS] Alcohol Restrictions
Participants will refrain from consumption of alcohol 24 hours prior to the pres tudy visit until 
after the visit, and from 24 hrs prior to Day -1 until the completion of Day  9 (ie, 168hr post 
ISL dose) procedures . At all other times, alcohol consumption is limited to no more than 
approximately  3 alcoholic beverages or equivalent (1 gl ass is approximately  equivalent to: 
beer [354 mL /12 ounces], wine [118 mL/4 ounces], or distilled spi[INVESTIGATOR_2120] [29.5 mL /1 ounce]) per 
day.
[IP_ADDRESS] Tobacco Restrictions
Smoking will be limited to no more than [ADDRESS_632080] dose on Day s 1 and 2. I n addition, 
participants will follow the smoking restrictions defined b y the CRU.
5.3.3 Activity Restrictions
Participants will avoid unaccustomed strenuous phy sical activity  (ie, weightlifting ,running, 
bicycling, etc.) from the prestudy  (screening) visit until discharge from the clinic on Day  9.
5.[ADDRESS_632081]:   MK-8591  41
PROTOCOL/AMENDMENT N O.:  029 -00  
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
demograph y, screen failure details, eligibility criteria, and an y AEs or SAEs meeting 
reporting requirements.
5.5 Participant Replacement Strategy
If a participant withdraws from the study a replacement participant may  be enrolled if 
deemed appropriate b y the investigator and Sponsor. The replacement participant will 
generall y receive the same intervention or intervention sequence (as appropriate) as the 
participant being replaced. The replacement participant will be assigned a unique 
treatment/randomization number. The stud y site should contact [CONTACT_111948]’s treatment/randomization number.
The replacement participant may  begin dosing at the subsequent dose level for that panel, 
based on investigator and Sponsor review and discussion.
6 STUDY INTERVENTION
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) intended to be administered to a study  participant according to 
the study  protocol .
Clinical supplie s of ISLwill be packaged to support enrollment and r eplacement participants 
as required. When a replacement participant is required, the Sponsor or designee needs to be 
contact[CONTACT_111949]. Clinical supplies will be affixed with a 
clinical label in accordance with regulator y requirement s.
6.1 Study Intervention(s) Administered
The study intervention (s) to be used in this study are outlined inTable [ADDRESS_632082]: MK-8591  42
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Table 1 Study  Intervention s
Arm  Nam eArm  
TypeIntervention 
Nam eInter -
vention 
TypeDose 
Form ulationUnit Dose 
Strength(s)Dosage 
Level(s)Route of 
Adminis-
trationRegim en/
Treatm ent 
Period/
Vaccination 
Regim enUseIMP/
NIMPSourcing
Run-in Experi
mentalMethadone Drug Per Local 
GuidelinesVaries 20-[ADDRESS_632083] (IMP) and Non-Investigational Medicinal Product (NIMP) in this table is based on guidan ce issued by [CONTACT_111951] (EEA). Country differences with respect to the definition /classification of IMP/NIMP may exist. In these 
circumstances, local legislation is followed. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  43
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
All supplies indicated in Table 1 will be provided per the "Sourcing" column depending upon 
local country  operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/bat ch number where possible.
Refer to Section 8.1.8 for details regarding administration of the study  intervention.
6.2 Preparation/Handling/Storage/Accountability
6.2.[ADDRESS_632084] be stored 
in a secure, environmentally  controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y intervention accountability , reconciliation, and record maintenance (ie, 
receipt, reconcil iation, and final disposition records).
For all stud y sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study  site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_491479] (if applicable) as per local guidelines unless otherwise 
instructed by  [CONTACT_1034].
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of stud y 
interventions in accordance with the protocol and any  applicable laws and regulations . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  44
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Participants in this trial will be allocated b y non -random assignment as shown i n Table 2. 
Table 2 Sample Allocation Schedule
Subjects Day 1 Day 2 
N=14 Single oral dose of methadone 20 
–200mg Single oral dose of m ethadone 20 –
200mg + ISL 60 mg
6.3.2 Stratification
No stratification based on age, sex or other characteristics will be used in this trial.
6.3.3 Blinding
This is a single treatment arm open -label study ; therefore, the Sponsor, investigator, and 
participant will know the intervention administered.
6.[ADDRESS_632085] dose of methadone run -in therapy , they may be included in the study  if the investigator 
can rationalize that the specific use of a prior medication is not clinically relevant within the 
context of the study .
Concurrent use of an y prescription or nonprescription medication, or concurrent vaccination,
during the ongoing stud y (ie, after run -in maintenance phase begins )until the follow -up call
must first be discussed between the investigator and Sp onsor prior to administration, unless 
appropriate medical care necessitates that therap y or vaccination should begin before the 
investigator and Sponsor can consult. The participant will be allowed to continue in the study  
if both the Sponsor and the inves tigator agree.
Paracetamol/acetaminophen at ≤2000 mg total daily  dose may be used for minor ailments 
without prior consultation with the Sponsor.
In addition, the following concomitant medications are permitted:
1. The participants’ prescribed methadone treatment . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  45
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
2. The concomitant use of benzodiazepi[INVESTIGATOR_491480] a stable benzodiazepi[INVESTIGATOR_67910] (as prescribed by a 
physician) for at least [ADDRESS_632086] be discussed with Sponsor prior to enrollment.
3. Truvada® or Descov y® for the prevention of HIV -infect ion, provided the participant 
initiate suse of these products no later than the start of the 14- day run-in period or 
after the Day  9 clinic discharge.
6.5.1 Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study .
6.6 Dose Modification
Not applicable.
6.7 Intervention After the End of the Study
There is no stud y-specified intervention following the end of the stud y.
6.8 Clinical Supplies Disclosure
This study  is open -label; therefore, the participant, the study  site personnel, the Sponsor, 
and/or designee are not blinded. Study  intervention (name, st rength, or potency ) is included 
in the label text; random code/disclosure envelopes or lists are not provided.
6.[ADDRESS_632087] the appropriate 
controlled drug license(s) as mandated b y Federal, State, Province, Country , etc., laws in 
which the study  is being conducted.
[ADDRESS_632088] be collected through the participant’s last scheduled follow-
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study  intervention prior to completion of the protocol -specified treatment 
period will still continue to participate in the study as specified in Section 1.[ADDRESS_632089]: MK-8591  46
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632090] 
occur. In addition, a participant may  be discontinued from stud y inte rvention by  [CONTACT_443157], the stud y plan is violated, or 
for administrative and/or other safet y reasons. Specific details regarding procedures to be 
performed at study  intervention discontinuation a re provided in Sections 8.1.[ADDRESS_632091] be discontinued from study intervention but continue to be monitored in 
the study  for an y of the following reasons:
•The participant or participant’s legall y acceptable representative requests to discontinue 
study  intervention.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The p articipant has a confirmed positive serum pregnancy  test.
•The participant requires a dose adjustment to their methadone treatment which, in the 
opi[INVESTIGATOR_11922]/or Sponsor, would interfere with the scientific integrity  of 
the trial.
7.[ADDRESS_632092] be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study , they  will no longer receive stud y intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study ,as well as specific details regarding withdrawal from future biomedical r esearch, are 
outlined in Se ction 8.1.9. The procedures to be performed should a participant repeatedl y fail 
to return for scheduled visits and/or if the study  site is unable to contact [CONTACT_111953] 7.3.
7.[ADDRESS_632093] t o Follow -up
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. I f the 
participant is c ontacted, the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•The investigator or designee must make every  effort to regain contact [CONTACT_19424] (eg, telephone calls and/o r a certified letter to the participant’s last  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  47
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
known mailing address or locally equivalent methods). These contact [CONTACT_19425]’s medical record.
•Note: A participant is not considered lost to follow -up until the last sch eduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified statistical data handling and anal ysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study  procedures and their timing are summarized in the SoA.
•Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
•The investigator is responsible for ensuring that procedures are conducted by  
[CONTACT_11399] y qualified (by  [CONTACT_8640], tra ining, and experience) staff. Delegation of study  
site personnel responsibilities will be docu mented in the I nvestigator Trial File Binder (or 
equivalent).
•All study -related medica l (or dental) decisions must be made b y an investigator who is a 
qualified phy sician (or dentist when appropriate) .
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants scre ened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may  be utilized for screening or base line 
purposes provided the procedure met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.
•Additional evaluations/testing may  be deemed necessary  by [CONTACT_491487] y. In some cases, such evaluation/testing 
may be potentially  sensitive in nature (eg, HIV, Hepatitis C), and thus local regulations 
may require that additional informed consent be obtained from the participant. I n these 
cases, such evaluations/ testing will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 241mL[Appendix 8].
Repeat or unscheduled samples may  be taken for safet y reasons or for technical issues with 
the samples. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  48
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically  qualified designee (consistent with local requirements) must 
obtain documented consent from each potential participant or each participant’s legall y 
acceptable representative prior to participating in a clinical stud yor future biomedical 
research . If there are changes to the participant’s status during the stud y (eg, health or age of 
majority  requirements), the investigator or medically  qualified designee must ensure the 
appropriate consent is in place.
[IP_ADDRESS] General Informed Consent
Consent must be documented by  [CONTACT_2299]’s dated signature [INVESTIGATOR_1660] b y the participa nt’s 
legally  acceptable representative’s dated signature [INVESTIGATOR_2394] a consent form along with the dated 
signature [CONTACT_63564].
A cop y of the signed and dated consent form should be given to the participant before 
participation i n the study .
The initial I CF, any  subsequent revised written ICF, and an y written information provided to 
the participant must receive the IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally  acceptable representative should be informed in a timely  manner 
if new information becomes available that may  be relevant to the participant’s willingness to 
continue participation in the study . The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s dated signature [INVESTIGATOR_1660] b y the participant’s legall y acceptable 
representative’s dated signature.
If the investigator recommends continuation of study  intervention bey ond disease
progression, t he participant or his/her legally  acceptable representative will be asked to sign 
consent.
Specifics about a stud y and the study population will be added to the consent form template 
at the protocol level.
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, 
and Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically  qualified designee will explain the future biomedical r esearch 
consent to the participant, answer all of his/her questions, and obtain written informed 
consent before performin g any procedure related to future biomedical research. A cop y of the 
informed consent will be given to the participant. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  49
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study .
8.1.[ADDRESS_632094] information (including direct 
telephone numbers) to be used in the event of an emergency . The investigator or qualified 
designee will provide the participant with a participant identification card immediately  after 
the participant provides written informed consent. At the time of intervention allocation, site 
personnel will add the treatment /randomization number to the participant identification card.
The participan t identification card also contains contact [CONTACT_75345] a health care provider can obtain information about study  
intervention in emergency  situations where the investigator is not available.
8.1.4 Medical History
A medical history  will be obtained by  [CONTACT_27404].
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication use, including an y 
protocol -specified washout requirement, and record prior medication taken by  [CONTACT_88688] 28 day s before the start of the methadone run- in phase .
[IP_ADDRESS] Concomitant M edications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_63525] y.
8.1.[ADDRESS_632095] not be 
re-used for different participants.
8.1.7 Assignment of Treatment/Randomization Numb er
All eligible partici pants will be allocated, b y non random assignment, and will receive a 
treatment /randomization number. The treatment /randomization number identifies the 
participant for all procedures occurring after treatment allocation.  Once a  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  50
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
treatment /randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
During the methadone run -in phase, participants will retrieve the stable daily  dose of 
methadone from their usual local methadone clinic and self -administer as directed for 14 
days. 
On Day s 1-9 , administration of study  medication will be witnessed by  [CONTACT_1755]/or 
study  staff. Approximately  240 mL of water will be provided during trial drug 
administration. Additional water may be provided in ~[ADDRESS_632096] until the follow -
up call .
[IP_ADDRESS] Timing of Dose Administration
Methadone will be administered in the morning of Day  [ADDRESS_632097] with 
approximately  240 mL of water (regardless of formulation). Participants should continue to 
fast until at least [ADDRESS_632098] (methadone to be administered first at 
approximately  the same time as on Day 1). A total of [ADDRESS_632099] 4 hours postdose.
The time of methadone administration will be deemed Time “0” and stud y assessments will 
be relative to this.  
8.1.[ADDRESS_632100] notify the Sponsor when a participant has been 
discontinued/withdrawn from the study and/or intervention. If a participant discontinues for 
any reason at any  time during the course of the study  and/or intervention, the partic ipant may  
be asked to return to the clinic (or be contact[INVESTIGATOR_530]) for a poststudy  visit as per the number of 
days described in Section 8.4.[ADDRESS_632101]: MK-8591  51
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
(Section 8.4.1) to confirm if any  AEs have occurred since the poststud y clinic visit. Any  
AEs that are present at the time of discontinuation/withdrawal should be followed in 
accordance with the saf ety requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may  withdraw their consent for future biomedical r esearch. Participants may  
withdraw consent at an y time by  [CONTACT_111954] . Ifmedical 
records for the main study are still available, the investigator will contact [CONTACT_111955] ([EMAIL_1250]). Subsequently ,the 
participant's consent for future biomedical r esearch will be withdra wn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. I t is the responsibility  of the 
investigator to inform the participant of completion of withdrawal. An y analy ses in progress 
at the time of request for withdrawal or alread y performed prior to the request being received 
by [CONTACT_443171]. 
No new analy ses would be generated after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main study records) 
or the specimens have been completel y anon ymized, there will no longer be a link between 
the parti cipant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
8.1.10 Participant Blinding/Unblindi ng
This is an open -label study ; there is no blinding for this study .
8.1.11 Domicili ng
Participants will report to the CRU on Day  -1and remain in the unit until 168 hrs postdose of 
concomitant methadone and I SL administration ( ie, Day  9). At the discretion of the 
investigator, participants may  be requested to remain in the CRU longer.
8.1.12 Calib ration of Equipme nt
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinica l study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site.
8.2 Efficacy/Immunogeni cityAssessmen ts
There are no direct efficacy assessments in this study . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  52
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.3 Safety Assessments
Details regarding specific safet y procedures/assessments to be performed in this study  are 
provided. The total amount of blood to be drawn/collected over the course of the study  (from 
prestudy  to poststudy  visits), including approximate blood volumes drawn by  [CONTACT_234530] b y 
sample ty pe per participant, can be found in Section 8.
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete ph ysical examination will be conducted by [CONTACT_63534] (consistent with local requirements) as per institutional standard. Height and weight 
will also be measured and recorded.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
BMI
BMI equals a person's weight in kilograms divided by  [CONTACT_55739] 
(BMI=kg/m2). BMIwill be rounded to the nearest whole number according to the standard 
convent ion of 0.1 to 0.4 round down and 0.5 to 0.9 round up.
Body weight and height will be obtained with the participant’s shoes off and jacket or coat 
removed.
8.3.2 Vital Signs
Temperature, HR, BP, RR and oxy gen saturation (via pulse oximeter) will be assessed.
[IP_ADDRESS] Resting Vital Signs
Vital Sign Measurements (Heart Rate ,Blood Pressure , Respi[INVESTIGATOR_13581], Oxygen 
Saturation )
Participants should be resting in a quiet setting without distractions in a semirecumbent 
position for at least [ADDRESS_632102] 
positioning on the participant ’s arm is essential to increase the accuracy  of BP measurements.
The predose (baseline) HR and BP will be a single measurement obtained within 2hours of 
dosing methadone on Day  1. These measurements will be used as the baseline to calculate 
change from baseline for safety evaluations (and for rechecks, if needed). Postdose VS 
measurements will alsobe single measurements. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  53
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Respi[INVESTIGATOR_491481] (via pulse oximeter) will be measured per the site 
standard operating procedures. Participants should be resting in a semi -recumbent position 
for at least [ADDRESS_632103] be used for all measurements for 
each individual participant and should be the same for all participants.
8.3.3 Electrocardiograms
•12-lead ECG will be obtained and reviewed b y an investigator or medicall y qualified 
designee (consistent with local requirements) as outlined in the SoA using an ECG 
machine that automatically  calculates the heart rate and measures PR, QRS, QT, and QTc 
intervals. Refer to Appendix 10.9 for evaluation and withdrawal criteria and additional 
QTc readings that may  be necessary .
•At each time point when triplicate ECG sare required (ie, screening and Day  1 and 2 
predose) , [ADDRESS_632104] 1-2 minutes apart within 2 hours prior to 
dosing on Day s 1 and 2. The mean of these measurements will be used as the baseline to 
calculate change from baseline for safet y evaluations (and for rechecks, if needed).
If a participant demonstrates an increase in QTc interval ≥60 msec compared with mean 
predose bas eline measurement, the ECG will be repeated twice within 5 minutes. The mean 
value of the QTc interval from the 3 ECGs will represent the value at that time point. I f the 
mean QTc interval increase from baseline for an y postdose time point is ≥[ADDRESS_632105]: MK-8591  54
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
interval ≥[ADDRESS_632106] may  be ap propriate and 
the Sponsor should be notified.
If the QRS duration from any  postdose ECG is 20% greater than the mean baseline QRS 
duration and is >120 msec (and change is not considered rate -related or pacing -induced) or 
there appears to be new onset inter mittent bundle branch block, then the ECG will be 
immediately  repeated twice within 5 minutes. The mean value of the QRS interval from the 3 
ECGs will represent the value at that time point. If the mean QRS interval increase from 
baseline for an y postdose time point is >20%, the participant will continue to be monitored 
by [CONTACT_7850] [ADDRESS_632107] 1 hour or until the QRS is within 20% 
of baseline. If a >20% prolongation of the QRS interval persists, a consultation with a 
cardiologis t may  be appropriate and the Sponsor should be notified.
If the QTc interval is ≥[ADDRESS_632108]. The participant should be telemetry -
monitored (until the QTc is <500 msec) or should be considered for transfer to a location 
where closer monitoring and definitive care (eg, a cardiac or intensive care unit) is available.
If the QRS duration is prolonged b y more than 20% compared to the mean baseline, and is 
≥200 mse c (and change is not considered rate -related or pacing -induced), then the Sponsor 
should be notified. The ECGs should be reviewed by  a cardiologist and the participant should 
be considered for transfer to a location where closer monitoring and definitive c are (eg, a 
cardiac or intensive care unit) is available.
If the participant has unstable hemod ynamics, or has an y clinicall y significant dysrh ythmias 
noted on telemetry , the participant should be immediatel y transferred to an acute care setting 
for definit ive therap y.
If prolongation of the QTc is noted, concomitant medications that prolong QTc should be 
held until the QTc is within 60 msec of baseline and the QTc is <[ADDRESS_632109] will be consulted by  [CONTACT_491488].
8.3.4 Clinical Opi[INVESTIGATOR_2433] (COWS)
The COWS will be administered at screening and at predose on Day  1 to establish a baseline .
COWS will only  be administered at other timepoints if overt signs of withdrawal are 
observed and it is determined clinically appropriate to administer COWS assessment. To 
minimize variability , it is preferred (but not required) that a participant be assessed by  [CONTACT_491489]. Instructions on administering the COWS 
assessment can be found in the operations/laboratory  manual . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  55
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632110] of clinical laboratory  tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically  qualified designee (consistent with local requirements) 
must review the laboratory  report, document this review, and record an y clinically 
relevant changes occurring during the stud y in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically  significant abnormal 
laboratory  findings are those which are not associated with the underl ying disease, unless 
judged by [CONTACT_19448]'s condition.
•All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA .
•If laboratory  values from nonprotocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in study  participant management or are 
considered clinically  significant by  [CONTACT_093] (eg, SAE or AE or dose 
modification), then the resu lts must be recorded in the appropriate CRF (eg, SL AB).
•For an y laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 7daysafter the last dose of study  intervention, every  
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by  [CONTACT_093] .
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or S AE, as well as the method of recording, evaluating, and 
assessing causalit y of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safet y event reports can be found in Appendix 3.
Adverse events, SAEs, and other repo rtable safety events will be reported by  [CONTACT_2299] 
(or, when appropriate, b y a caregiver, surrogate, or the participant's legall y authorized 
representative).
The investigator and an y designees are responsible for detecting, documenting, and reporting
events that meet the definition of an AE or SAE as well as other reportable safet y events. 
Investigators remain responsible for following up AEs , SAEs, and other reportable safety  
events for outcome according to Section 8.4.3.
The investigator, who is a qualified ph ysician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safet y events with respect to seriousness, 
intensity /toxicity  and causality . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  56
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632111] be reported immediately  to the Sponsor 
if the event is considered related to stud y intervention.
Investigators are not obligated to activel y seek AE sor SAEs or other reportable safety  events 
in former stud y participants. However, if the investigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonabl y related to the study intervention or study  participation, 
the investigator must promptly  notify  the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety  events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3 .
Table 3 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time Period:
Consent to 
Randomization/ 
Allocation
(Randomized 
participants only)Reporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -specified 
Follow -up PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified intervention
- causes exclusion
-participant is 
receiving placebo run -
in or other run -in 
treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is 
receiving placebo run-
in or other run -in 
treatmentReport all Report if:
-drug/vaccine 
related.
(Follow  ongoing 
to outcome)Within [ADDRESS_632112]: MK-8591  57
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Type of Event Reporting Time Period:
Consent to 
Randomization/ 
Allocation
(Randomized 
participants only)Reporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -specified 
Follow -up PeriodTime Frame to 
Report Event and 
Follow -up 
Information to 
Sponsor:
Pregnancy/
Lactation 
ExposureReport if:
-participant has been 
exposed to any 
protocol -specified 
intervention (eg, 
procedure, w ashout or 
run-in treatment 
including placebo run -
in)Report all Previously 
reported – Follow  
to 
completion/termin
ation; report 
outcomeWithin 24 hours 
of learning of 
event
ECI (require 
regulatory 
reporting)Report if:
-due to interventi on
-causes exclusionReport
-potential DILI
-require regulatory 
reportingNot required Within 24 hours 
of learning of 
event
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 calendar 
days of learning 
of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 calendar 
days of learning 
of event
(unless serious)
Overdose Report if:
-receiving placebo run -
in or other run -in 
medication Report all Not required Within 24 hours 
of learning of 
event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
even t
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safet y events. Open -ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report , the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safet y events ,
including pregnancy  and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3 ). In addition, the investigator will 
make every  attempt to follow all nonserious AEs that occur in allocated participants for 
outcome. Further information on follow -up procedures is given in Appendix 3. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  58
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_126543] y of participants and the 
safety of a stud y intervention under clinical investigation are m et.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply  with country -specific regulatory  requirements and global laws and 
regulations relating to safety  reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and Sponsor policy  and forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safet y information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify  the IRB/IEC, if ap propriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Information in this section is not applicable sin ce participants are males and non-pregnant, 
non-breastfeeding females .
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable.
8.4.[ADDRESS_632113] for this study  include: 
1. An overdose of Sp onsor's product, as defined in Section 8.5.
2. An elevated AST or ALT lab value that is greater than or equal to 3X the 
upper limit of normal and an elevated total bilirubin lab value that is greater 
than or equal to 2X the upper limit of normal and, at the s ame time, an 
alkaline phosphatase lab value that is less than 2X the upper limit of normal, 
as determined b y wa y of protocol -specified laboratory  testing or unscheduled 
laboratory  testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify  a threshold of abnormal hepatic tests that must trigger 
an additional evaluation for an underl ying etiology. The study  site guidance for  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  59
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
assessment and follow up of these criteria can be found in the In vestigator Study  File 
Binder (or equivalent).
It may  also be appropriate to conduct additional evaluation for an underl ying etiology  in the 
setting of abnormalities of liver blood tests including AST, ALT, bilirubin, and alkaline 
phosphatase that do not me et the criteria noted above. In these cases, the decision to proceed 
with additional evaluation will be made through consultation between the study  investigators 
and the Sponsor Clinical Director. However, abnormalities of liver blood tests that do not 
meet the criteria noted above are not ECIs for this study .
8.5 Treatment of Overdose
For purposes of this study, an overdose will be defined as an y dose of an y drug administered 
as part of the stud y exceeding the dose prescribed by  [CONTACT_760]. It is up to the i nvestigator 
or the reporting ph ysician to decide whether a dose is to be considered an overdose, in 
consultation with the Sponsor.
8.6 Pharmacokinetics
The decision as to which plasma samples collected will be assay ed for evaluation of 
PK/pharmacod ynamics wil l be collaborativel y determined by [CONTACT_1034] (eg, samples at 
lower doses may  not be assay ed if samples at higher doses reveal undetectable drug 
concentrations). If indicated, these samples may also be assayed and/or pooled for assay in an 
exploratory  manner for metabolites and/or additional pharmacod ynamic markers .
8.6.1 Bloo d Collection for Plasma ISL and Plasma Methadone
Sample collection, storage, and shipment instructions for plasma samples will be provided in 
the operations/laboratory manual .
8.7 Pharmacodynamics
Pharmacod ynamic parameters will not be evaluated in this study .
8.8 Biomarkers
Collection of samples for other biomarker research is also part of this study . The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA:
•Blood for Genetic Analysi s
8.8.1 Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected,  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  60
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
leftover extracted DNA will be stored for future biomedical research. If the planned genetic 
analysis is not approved, but future biomedical research is a pproved, this sample will be 
collected for the purpose of future biomedical research.
Sample collection, storage, and shipment instruction for planned genetic analysis samples 
will be provided in the operations/laboratory manual.
8.9 Future Biomedical Research Sample Collection
If the participant signs the future biomedical r esearch consent, the following specime ns will 
be obtained as part of future biomedical r esearch:
•Leftover DNA for future research
8.10 Visit Requirements
Visit requirements are outlined in Secti on 1.3. Specific procedure -related details areprovided 
inSection 8.
8.10.1 Screening
Approximately  4weeks prior to intervention allocation, potential participants will be 
evaluated to determine that they  fulfill the entry  requirements as set forth in Section 5 .
Participants may  be rescreened after consultation with the Sponsor. Rescreening should 
include all screening procedures listed in the SoA, including consent review. Rescreen 
procedures cannot be conducted the day  prior to intervention allocation if there are Day  -1 
procedures planned per protocol.
8.10.2 Treatment Period
Refer to Schedule of Activities (Section 1.3).
8.10.3 Discontinued Participants Continuing to be Monitored in the Study
At any  point if a participant discontinues from treatment but continues to be monitored in the 
study , a subset of stud y procedures specified in the SoA may  be completed at the discretion 
of the investigator and with Sponsor agreement. The subset of study procedures completed 
will be communicated in a PCL .
8.10.4 Posts tudy
Participants will receive a follow -up call 14 day s (+3 day s) after receiving the dose of ISL for 
assessment of AEs and reporting of concomitant medications . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  61
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
8.10.5 Critical Procedures Based on Study Objectives: Timing of Procedure
For this study , blood sample sfor methadone and ISL pharmacokinetics are the critical 
procedure s.
The blood collection for ISL pharmacokinetics should be based upon the time of ISL
administration. The blood collection for methadone should be based upon the time of 
methadone administration.
At any  postdose timepoint, the blood sample sfor methadone and ISL need to be collected as 
close to the exact timepoint as possible. All other procedures should be completed as close to 
the prescribed/scheduled time as possible.
The order of priorit y can be changed du ring the study  with joint agreement of the investigator 
and the Sponsor Clinical Director.
Any nonscheduled procedures required for urgent evaluation of safet y concerns take 
precedence over all routine scheduled procedures.
The following variance in proced ure collection times will be permitted.
•PK Collection as outlined in Table 4 .
Table 4 Pharmacokinetic Blood Collection Windows
PK Collection PK Collection Window
0 -<1 hr ±5 min
1 -<24 hr ±15 min
24-<48hr ±1 hr
48-168 hr ± 2 hr
•Predose standard safet y evaluations: vital signs and ECG within 3 hrs prior to dosing on 
Days 1 and 2 ;COWS within 1 hr predose on Day s 1 and 2; laboratory  safety  tests and 
physical exam within 24 hrs prior to dosing on Day  1
•Postdose standard safet y evaluations : vital signs, ECG, laboratory  safet y tests <24 hr 
postdose (Day  1 and Day 2) may be obtained within ±15 min of the theoretical sampling 
time
-24 hr - <48 hr postdose (Day  2) may  be obtained within ± 1 hr of the theoretical 
sampling time
-48 hr – 168 hr postdose (Day  2) may  be obtained within ± [ADDRESS_632114]: MK-8591  62
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
->168 hr postdose (Day  2) may  be obtained within ± 24 hr of the theoretical sampling 
time
8.10.6 Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
This is a Phase 1 assessment of ISL in humans, and the PK, pharmacod ynamic, and safet y 
profiles of the compound arestill being elucidated. This protocol is written with some 
flexibility  to accommodate the inherent d ynamic nature of Phase 1 clinical studies. 
Modifications to the dose, dosing regimen, and/or clinical or laboratory  procedures currently  
outlined may  be re quired to achieve the scientific goals of the study  objectives and/or to 
ensure appropriate safet y monitoring of the stud y participants.
As such, some alterations from the currentl y outlined dose and/or dosing regimen may be 
permitted based on newly availa ble data, but the maximum daily  dose may  not exceed those 
currentl y outlined in the protocol.
•Decrease in the dose of the study  intervention administered
•Instructions to take study intervention with or without food or drink may also be modified 
based on ne wly available data
•Modification of the PK/pharmacod ynamic sample processing and shippi[INVESTIGATOR_491482]/pharmacod ynamic sampling scheme currently  outlined in the protocol may  be 
modified during the study based on newl y availab le PK or pharmacod ynamic data (eg, to 
obtain data closer to the time of peak plasma concentrations). If indicated, these collected 
samples may  also be assay ed in an exploratory  manner for metabolites and/or additional 
pharmacod ynamic markers.
Up to anadditional 50 mL of blood may  be drawn for safety, PK, and/or pharmacody namic 
analyses. The total blood volume withdrawn from any single participant will not exceed the 
maximum allowable volume during his/her participation in the entire study (Appendix 8).
Thetiming of procedures for assessment of safet y procedures (eg, vital signs, ECG, safet y 
laboratory  tests, etc.) may  be modified during the study  based on newl y available data. 
Additional laboratory  safety  tests may  be added to blood samples previously  draw n to obtain 
additional safet y information. These changes will not increase the number of study 
procedures for a given participant during his/her participation in the entire study .
It is understood that the current stud y ma y emplo y some or none of the alterations described 
above. An y alteration made to this protocol to meet the study objectives must be detailed b y 
the Sponsor in a letter to the Study  File and forwarded to the investigator for retention. The 
letter may  be forwarded to the I RB/IEC at the discr etion of the investigator . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  63
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
9 STATISTICAL ANALYSIS PLAN
9.1 Statistical Analysis Plan Summary
This section contains a summary  of the statistical anal yses for this trial. Full detail is in the 
Statistical Methods (Section 9.6).
Effect of ISL on Methadone 
Primary Hypotheses
AUC 0-24for methadone R -enantiomer will be dose -normalized by  [CONTACT_6992]’s methadone 
dose before the statistical anal yses. A natural log transformation will be applied to the R -
methadone AUC0 -24/D prior to t he anal ysis.A linear mixed- effects model will be used to 
evaluate the primary  hypothesis.  The model includes a fixed effect term for treatment.  An 
unstructured covariance matrix will be used to allow for unequal treatment variances and to 
model the corr elation between the two treatment measurements within each subject via the 
REPEATED statement in SAS PROC MI XED.  Kenward and Roger's method will be used to 
calculate the denominator degrees of freedom for the fixed effects (DDFM=KR).  A ninet y 
percent (90 %) confidence interval (CI) will be constructed for the difference in L S means on 
the log scale R -methadone AUC0 -24/D .  Exponentiating the log -scale 90% CI  will provide a 
90% CI  for the AUC0 -24/D geometric mean ratio ( GMR) (methadone+ISL/methadone 
alone). The h ypothesis that the methadone (R -enantiomer) AUC0- 24 obtained after single 
dose co -administration of methadone with I SL is similar to the methadone (R -enantiomer) 
AUC 0-24obtained after single dose administration of methadone alone will be supported i f 
the 90% CI for the AUC 0-24/D GMR of R -methadone is contained within the interval (0.70, 
1.43). 
AUC0 -24 for methadone S -enantiomer will be analy zed based on the same model. The GMR 
(methadone+I SL/methadone alone) and 90% CI for methadone S -enantiomer will be 
estimated. The h ypothesis that the methadone ( S-enantiomer) AUC0- 24 obtained after single 
dose co -administration of methadone with I SL is similar to the methadone ( S-enantiomer) 
AUC 0-24obtained after single dose administration of methad one alone will be supported if 
the 90% CI for the AUC 0-24/D GMR of S-methadone is below 2.0. 
Secondary Hypothes es
Dose normalized Cmax of R-and S -enantiomer will also be analy zed based on the same 
model. The GMR s(methadone+ISL/methadone alone) and 90% CIsfor each parameter will 
be estimated. The h ypothesis that the methadone ( R-enantiomer) Cmax obtained after single 
dose co -administration of methadone with I SL is similar to the methadone (R -enantiomer) 
Cmax obtained after single dose administration of methadone alone will be supported if the 
90% CI  for the Cmax /D GMR of R-methadone is below 1.43. The h ypothesis that the 
methadone ( S-enantiomer) Cmax obtained after single dose co- administration of methadone 
with I SL is similar to the methadone ( S-enantiomer) Cmax obtained after single dose 
administration of methadone alone will be supported if the 90% CI for the Cmax /D GMR of 
S-methadone is below 2.0.   
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  64
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Estimations
Dose normalized C24 of R -methadone and S- methadone , and dose normalized AUC0 -24, 
Cmax and C24 of methadone total will be anal yzed similarly  using the above model.  The 
GMR (methadone+I SL/methadone alone) and 90% CI  for every  afore -mentioned parameter 
will be estimated. Geometric means (GMs) and corresponding 95% CIs will also be provided
for AUC0 -24/D, Cmax/D and C24/D of methadone (R -, S-, and total methadone) by 
[CONTACT_3148].  Plots with the individual ratios, GMR and 90% confidence interval will be 
provided for AUC0 -24/D, Cmax/D and C24/D of methadone (R -, S-, and total methadone) . 
Explo ratory - Effect of Methadone on ISL
ISL AUC 0-24will be compared with the most appropriate available historical data following 
administration of MK -8591 60 mg alone. Potential historical data tobe used include MK -
8591 P026 and P030. I SL AUC0 -24 following co -administration of methadone and ISL and 
the historical data will be natural log transformed and anal yzed using an ANOVA model with 
a factor for treatment (methadone+I SL, ISL alone) . A ninet y percent (90%) CI will be 
constructed for the difference in LS means on the log scale ISLAUC0 -24. Exponentiating 
the log -scale 90% CI will provide a 90% CI for the AUC0 -24 GMR (methadone+ISL/ ISL 
alone). Similarly , ISL AUC0- 168, AUC0 -672, AUC0- inf, and Cmax will be anal yzed and 
compared with historical data. GMs and corresponding 95% CIs willalso be provided by 
[CONTACT_3148].  
Safety
Summary  statistics and plots will be generated for raw laboratory  safet y tests, ECGs, and/or
VS as well as for change from baseline, as deemed clinically appropriate. Depending on the
safet y parameter, the difference from baseline will either be computed on the original scale
(raw change from baseline) or on the log scale and back -transformed for reporting (percent
change from baseline). AEs will be listed and tabulated.
Sample Size and Power Calculations 
The following po wer estimates are based on within- subject SD obtained from MK -1439 
Protocol 045. With a sample size of 12 completers, i f the true GMR of R -methadone AUC0-
24hr/D(methadone+ISL/methadone alone) is 1.00, then there is a greater than 99% 
probability  of observing the 90% CI for the GMR within (0.70, 1.43) for R -methadone 
AUC0 -24hr/D; if the true GMR of S- methadone AUC0- 24hr/D(methadone+I SL/methadone 
alone) is 1.00, then there is a greater than 99% probability  of observing the 90% CI  for the 
GMR below 2.0 for S-methadone AUC0- 24hr/D. Overall, there is a 98% probability to meet 
the two primary  hypotheses. With a sample size of [ADDRESS_632115] 80% probability  that the 
90% CI for R-methadone AUC0 -24hr/Dis between (0.70, 1.43 ); ifthe true GMR of S-
methadone AUC0 -24hr is less than 1.[ADDRESS_632116] 80% probability  that the 90% 
CI for S-methadone AUC0 -24hr/Dis less than 2.0. A total of [ADDRESS_632117]: MK-8591  65
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632118] auspi[INVESTIGATOR_26338], the Early Clinical Development Statistics Department in collaboration 
with the Quantitative Pharmacology  and Pharmacometrics Department and Translational 
Pharmacology  Department of the Sponsor.
If, after the stud y has begun, changes are made to the statistical anal ysis plan stated below, 
then these deviations t o the plan will be listed, along with an explanation as to why they 
occurred, in the Clinical Study  Report.
9.3 Hypotheses/Estimation
Primary  Hypotheses: 
The methadone (R -enantiomer) plasma AUC0- 24 obtained after single dose co-
administration of methadone wi th ISL is similar to the methadone (R -enantiomer) plasma 
AUC0 -24 obtained after single dose administration of methadone alone. That is, the true 
GMR (methadone and ISL/methadone alone) for the dose -normalized AUC0 -24 (AUC0 -
24/D) of methadone (R -enantiomer) is contained within (0.7, 1.43 ).
The methadone (S -enantiomer) plasma AUC0- 24 obtained after single dose co-
administration of methadone with I SL is similar to the methadone (S -enantiomer) plasma 
AUC0 -24 obtained after single dose administration of methadon e alone. That is, the true 
GMR (methadone and ISL/methadone alone) for the dose -normalized AUC0 -24 (AUC0 -
24/D) of methadone ( S-enantiomer) is less than 2.0.
Secondary  Hypotheses: 
The methadone (R -enantiomer) plasma Cmax obtained after single dose co-
administration of methadone with I SL is similar to the methadone (R -enantiomer) plasma 
Cmax obtained after singl e dose administration of methadone alone. That is, the true 
GMR (methadone and ISL/methadone alone) for the dose -normalized Cmax (Cmax /D) of 
methadone (R -enantiomer) is less than 1.43.
The methadone (S -enantiomer) plasma Cmax obtained after single dose co-
administration of methadone with I SL is similar to the methadone (S -enantiomer) plasma 
Cmax obtained after singl e dose administration of methadone al one. That is, the true 
GMR (methadone and ISL/methadone alone) for the dose -normalized Cmax (Cmax /D) of 
methadone ( S-enantiomer) is less than 2.0 .
Estimations: 
ThetrueGMR (methadone and ISL/ methadone alone) for the dose normalized C24 
(C24/D) of methadone (R -enantiomer and S -enantiomer ) will be estimated .
ThetrueGMR (methadone and ISL/methadone alone) for the dose normalized AUC0 -24 
(AUC0- 24/D), Cmax (Cmax/D) and C24 (C24/D) of methadone (total) will be estimated. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  66
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
9.4 Analysis Endpoints
Primary  Endpoints
The primary  PK endpoints include dose-normalized AUC0 -24 (AUC0- 24/D) of plasma 
methadone (R- and S -methadone).
Secondary  Endpoints 
The secondary  PK endpoints include dose-normalized Cmax (Cmax/D), C24 (C24/D), and 
Tmax of plasma methadone (R-, and S- enantiomer ), and dose-normalized AUC0 -24 (AUC0 -
24/D), Cmax (Cmax/D), C24 (C24/D), and Tmax of plasma methadone (total).
The secondary  safet y endpoints include adverse experiences, laboratory safety tests, ECGs, 
and VSs (HR, BP , RR, oxygen saturation ).
Exploratory  Endpoints
The exploratory  PK endpoints include AUC0- 24, AUC0- 168, AUC0 -672, AUC0 -inf, Cmax, 
Tmax and t1/2 of plasma I SL. 
9.5 Analysis Populations 
The following populations are defined for the analysis and reporting of data. All participants 
will be reported, and their data analy zed, according to the treatment(s) they actuall y received.
All Subjects as Treated (ASaT): The All Subjects as Treated Population consists of all 
participants who receive at least on e dose of treatment. This population will be used for 
assessments of safety  and tolerability .
Per-Protocol (PP): The Per -Protocol Population consists of the subset of participants who 
comply  with the protocol sufficiently  to ensure that generated data will be likely  to exhibit 
the effects of treatment, according to the underly ing scientific model. Compliance covers 
such considerations as exposure to treatment, availability  of measurements and absence of 
important protocol deviations. I mportant protocol devi ations will be identified to the extent 
possible prior to unblinding b y individuals responsible for data collection/compliance, and its 
analysis and interpretation. Any  participants or data values excluded from analy sis will be 
identified, along with their reason for exclusion, in the CSR. At the end of the study , all 
participants who are compliant with the study  procedure as aforementioned and have 
available data considered sufficient to exhibit the effect of treatment will be included in the 
Per-Protocol dataset. This population will be used for the PK anal yses. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  67
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632119]’s methadone 
dose before the statistical anal yses.A natural log transformation will be applied to the R -
methadone AUC0 -24/D prior to the anal ysis.A linear mixed- effects model will be used to 
evaluate the primary  hypothesis.  The model includes a fixed effect term for treatment.  An 
unstructured covariance matrix will be used to allow for unequal treatment variances and to 
model the correlation between the two treatment measurements within each subject via the 
REPEATED statement in SAS PROC MI XED.  Kenward and Roger's method will be u sed to 
calculate the denominator degrees of freedom for the fixed effects (DDFM=KR).  A ninet y 
percent (90%) confidence interval (CI) will be constructed for the difference in L S means on 
the log scale R -methadone AUC0 -24/D .  Exponentiating the log -scale 90% CI  will provide a 
90% CI  for the AUC0 -24/D geometric mean ratio ( GMR) (methadone+ ISL/methadone 
alone).  The h ypothesis that the methadone (R -enantiomer) AUC0- 24 obtained after single
dose co -administration of methadone w ith ISLis similar to the methadone (R -enantiomer) 
AUC 0-24obtained after single dose administration of methadone alone will be supported if 
the 90% CI for the AUC 0-24/D GMR of R -methadone is contained within the interval (0.70, 
1.43) . 
Sample SAS code is given below:
proc mixed data=dataset;
   class treatment subject;
   model y  = treatment/ddfm=kr;
   repeated treatment / subject=subject t ype=un;
run;
AUC0 -24 for methadone S -enantiomer will be analy zed based on the same model. The GMR 
(methadone+I SL/methadone alone) and 90% CI for methadone S -enantiomer will be 
estimated. The h ypothesis that the methadone ( S-enantiomer) AUC0- 24 obtained after single 
dose co -administration of methadone w ith ISL is similar to the methadone ( S-enantiomer) 
AUC 0-24obtained after single dose administration of methadone alone will be supported if 
the 90% CI for the AUC 0-24/D GMR of S-methadone is below 2.0. 
Secondary Hypothes es
Dose normalized Cmax of R-and S- enantiomer will also be analy zed based on the same 
model. The GMR s(methadone+ISL/methadone alone) and 90% CI sfor each parameter will 
be estimated. The h ypothesis that the methadone ( R-enantiomer) Cmax obtained after single 
dose co -administration of methadone with I SL is similar to the methadone (R -enantiomer) 
Cmax obtained after single dose administration of methadone alone will be supported if the  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  68
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
90% CI  for the Cmax /D GMR of R-methadone is below 1.43. The h ypothesis that the 
methadone ( S-enantiomer) Cmax obtained after single dose co- administration of methadone 
with I SL is similar to the methadone ( S-enantiomer) Cmax obtained after single dose 
administration of methadone alone will be supported if the 90% CI for the Cmax /D GMR of 
S-methadone is below 2.0.  
Estimations
Dose normalized C24 of R -methadone and S- methadone , and dose normalized AUC0 -24, 
Cmax and C24 of methadone total will be anal yzed similarly  using the above model.  The 
GMR (methadone+ ISL/methadone alone) and 90% CI  for every  aforementioned parameter 
will be estimated. Geometric means (GMs) and corresponding 95% CIs will also be provided 
for AUC0 -24/D, Cmax/D and C24/D of methadone (R -, S-, and total methadone) by 
[CONTACT_3148]. Plots with the individual ratios, GMR and 90% confidence interval will be 
provided for AUC0 -24/D, Cmax/D and C24/D of methadone (R -, S-, and total methadone) . 
Exploratory - Effect of Methadone on ISL
ISL AUC 0-24will be compared with the most appropriate available historical data following 
administration of MK -8591 60 mg alone. Potential historical data tobe used include MK -
8591 P026 and P030. I SL AUC0 -24 following co -administration of methadone and ISL and 
the historical data will be natural log transformed and anal yzed using an ANOVA model with 
a factor for treatment (methadone+I SL, ISL alone) . A ninet y percent (90%) CI will be 
constructed for the difference in LS means on the log scale ISLAUC0 -24. Exponentiating 
the log -scale 90% CI will provide a 90% CI for the AUC0 -24 GMR (methadone+ISL/ ISL 
alone). Similarly , ISL AUC0- 168, AUC0 -672, AUC0- inf, and Cmax will be anal yzed and 
compared with historical data. GMs and corresponding 95% CIs willalso be provided by 
[CONTACT_3148].  
Individual values will be listed for each PK parameter b y treatment and analy te including 
dose-normalized AUC0 -24 (AUC0 -24/D), Cmax (Cm ax/D), C24 (C24/D), and Tmax of 
plasma methadone (total, R -, and S- methadone), and AUC0 -24,AUC0 -168, AUC0 -672, 
AUC0 -inf, Cmax, Tmax and t1/2 of plasma I SL, and the following (non -model -based) 
descriptive statistics will be provided: N (number of subjects with non -missing data), 
arithmetic mean, standard deviation, arithmetic percent CV (calculated as [ADDRESS_632120] 
deviation/arithmetic mean), median, minimum, maximum, geometric mean, and geometric 
percent CV (calculated as  100 x sqrt( exp(s2) - 1), where s2 is the observed variance on the 
natural log- scale. 
Safety:
Summary  statistics and plots will be generated for raw laboratory  safet y tests, ECGs, and/or
VS as well as for change from baseline, as deemed clinically appropriate. Depending on the
safet y parameter, the difference from baseline will either be computed on the original scale
(raw change from baseline) or on the log scale and back -transformed for r eporting (percent
change from baseline). AEs will be listed and tabulated. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  69
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
9.7 Interim Analyses
Not applicable. 
9.8 Multiplicity
Since bot hprimary  hypothes es (R-and S -methadone plasma AUC0 -24) must be supported in 
order for the overall clinical h ypothesis to be supported, there is no need for a multiplicity  
adjustment . 
9.[ADDRESS_632121] SD obtained from MK -1439 
Protoc ol 045. 
With a sample size of 12 completers, i f the true GMR of R -methadone AUC0- 24hr/D
(methadone+ ISL/methadone alone) is 1.00, then there is a greater than 99% probability  of 
observing the 90% CI for the GMR within (0.70, 1.43) for R -methadone AUC0 -24hr/D; if 
the true GMR of S-methadone AUC0- 24hr/D(methadone+ISL/methadone alone) is 1.00, 
then there is a greater than 99% probability  of observing the 90% CI for the GMR below 2.0
for S-methadone AUC0- 24hr/D. Overall, there is a 98% probabilit yto meet the two primary  
hypotheses . 
With a sample size of [ADDRESS_632122] 80% probability  that the 90% CI for R-methadone 
AUC0 -24hr/Dis between (0.70, 1.43 ); ifthe true GMR of S-methadone AUC0 -24hr is less 
than 1.[ADDRESS_632123] 80% probability  that the 90% CI  for S-methadone AUC0-
24hr/Dis less than 2.0. 
Similar power calculations for R-, S-methadone Cmax/D and the precision estimation sfor
R-, S-methadone C24/D and total -methadone AUC0 -24/D, Cmax/D, and C 24/D are provided 
in Table [ADDRESS_632124]: MK-8591  70
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632125]
SD estimate
(log scale)BoundsPower if 
the True 
GMR is 
1.[ADDRESS_632126] and/or 
Highest True GMR 
to Maintain 80% 
Power
Prim ary Hypotheses 
R-methadone AUC0-24/D 0.088 (0.7, 1.43) 99% (0.77, 1.30)
S-methadone AUC0-24/D 0.116 <2.0 99% <1.76
Secondary Hypotheses
R-methadone Cmax/D 0.076 <1.43 99% <1.32
S-methadone Cmax/D 0.106 <2.0 99% <1.[ADDRESS_632127]
SD estimate
(log scale)Half-width of 90% CI 
(log scale)90% CI if the 
Estimated GMR is 
1.00
R-methadone C24/D 0.119 0.087 (0.92, 1.09) 
S-methadone C24/D 0.183 0.134 (0.87, 1.14) 
Total -methadoneAUC0-24/D 0.095 0.070 (0.93, 1.07) 
Cmax/D 0.087 0.064 (0.94, 1.07) 
C24/D 0.140 0.103 (0.90, 1.11)  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  71
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10 SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_632128] for Clinical Trials
[COMPANY_006] Sharp and Dohme Corp., a subsidiary of [COMPANY_006] & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all ca ses, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accor dance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investiga tor-initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacoki netic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary c onsiderations. Prior to trial 
initiation, sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  72
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632129] operating procedures. Per MSD policie s and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative ac tions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_491490].
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_26399] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulat ory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approva l. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of prim ary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of M SD), ethics committee, and/or regulatory authorities will have access to confidential medical records 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consen t authorized by [CONTACT_88709]. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  73
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
IV. Financial Considerations
A. Paym ents to Investigators
Clinical trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work perfo rmed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does no t pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that th e trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientifi c meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commit ment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, ag ree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54). I t is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.
The investigator/subinvestigator(s) agree, if requested by  [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investiga tor/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided b y 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
inform ation to the Sponsor in the [LOCATION_002] for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
10.1.[ADDRESS_632130]: MK-8591  74
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Participants will be assigned a unique identifier by [CONTACT_1034]. An y participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or an y information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that hi s/her medical records may  be examined by  [CONTACT_126560] S ponsor, by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities.
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_491491], the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC,or similar or expert committee; affiliated institution and 
employ ees, only  under an appropriate understanding of confidentialit y with such board or 
committee, affiliated institution and employ ees. Data generated b y this study will be 
considered confidential by [CONTACT_093], except to the extent that it is incl uded in a 
publication as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  represen tatives may  consult and/or cop y study  documents to 
verify  worksheet/ CRF data. By  [CONTACT_17317], the participant agrees to this 
process. If study  documents will be photocopi[INVESTIGATOR_75311]/ CRF information, the participant will be identified b y unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study  inaccordance with all applicable privacy  laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study . The Sponsor is also required to documen t that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request b y those agencies. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  75
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632131] 
proprietary  inform ation and to provide comments.
Authorship will be determined by  [CONTACT_11403] I nternational Committee 
of Medical Journal Editors authorship requirements .
10.1.5 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study  is solely  responsibl e for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study , will 
review this protocol and submi t the information necessary  to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify  potentiall y appropriate studies for their 
disease co nditions and pursue participation b y calling a central contact [CONTACT_126563].
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive ,or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this study  or its results to those 
registries.
10.1.[ADDRESS_632132] the study  in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of GCP
(eg, International C ouncil on Harmoni sation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP : Consolidated Guideline and other generall y accepted 
standards of GCP ); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study .
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y MSD, is provided i n this appendix 
under the Code of Conduct for Clinical Trials. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  76
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of an y regulatory authority in spection 
conducted for this study .
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection and will provide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical studies by  [CONTACT_63550]’s studies. The investigator 
will immediately  disclose in writing to the Sponsor if an y person who is involved in 
conducting the study  is debarred or if any  proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically  (eg, laboratory  data). The investigator 
or qualified designee is responsible for verify ing that data entries are accurate and correct b y 
physicall y or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investi gator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents.
Study  documentation will be promptly  and fully  disclosed to the Sponsor by [CONTACT_63551], 
copy ing, review, and audit at reasonable times b y repre sentatives of the Sponsor or an y 
regulatory  authorities. The investigator agrees to promptly  take an y reasonable steps that are 
requested b y the Sponsor or an y regulatory  authorit ies as a result of an audit or inspection to 
cure deficiencies in the stud y documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.
Study  monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  77
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632133] 
be retained b y the investigator for 15 years after study  completion unless local reg ulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor. No records may  be 
transferred to another location or part y without written notificati on to the Sponsor .
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study  records that include al lpertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary  (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent w ith the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study . Also, current medical records must be available .
10.1.9 Study and Site Closure
The Sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurel y terminates a particular stud y site, the Sponsor or 
designee will promptly  notify  that study  site’s IRB/IEC as specified b y applicable regulatory 
requirement(s). 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  78
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.2 Appendix 2: Clinical Laboratory Tests
•The tests detailed in Table 6will be performed b y the local laboratory .
•Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may  be performed at an y time during the stud y as determined necessary 
by [CONTACT_43215].
Table 6 Protocol -require d Safet yLaboratory  Assessments
Laboratory 
AssessmentsParameters
Hem atology Platelet Count WBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRBC Count
Hem oglobin
Hem atocrit
Chemistry Blood Urea 
Nitrogen (BUN)Potassium Aspartate 
Aminotransferase
(AST )Total and direct 
bilirubin 
Albumin Bicarbonate Chloride Phosphorous
Creatinine Sodium Alanine 
Aminotransferase
(ALT )Total Protein
Glucose (fasting ) Calcium Alkaline 
phosphatase
Routine 
Urinalysis•Specific gravity
•pH, glucose, protein, blood, ketones, [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by [CONTACT_5230]
•Microscopic examination (if blood or protein is abnormal)
Other Screening 
Tests•Follicle -stimulating hormone (as needed in women of nonchildbearing potential 
only)
•Urine drug screen (to include at minimum: amphetamines, barbiturates, cocaine, 
opi[INVESTIGATOR_858], cannabinoids and benzodiazepi[INVESTIGATOR_1651]) 
•Highly sensitive s erum  pregnancy test (for WOCBP )
•Serology (HIV antibody, hepatitis B surface antigen [HBsAg], and hepatitis C virus 
antib ody)
•Syphilis testing per standard of care (eg, treponemal and/or nontreponemal testing)
•Urine STI screen (to include at minimum: gonorrhea, chlamydia, trichomoniasis)
NOTES: Laboratory safety assessments will be performed after an [ADDRESS_632134]; however, in case of
discontinuation or rechecks, a non -fasting assessment may be performed at the discretion of the Investigator.
The i nvestigator (or medically  qualified designee) must document their review of each 
laboratory  safet y report. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  79
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE definition
    An AE is an y unto ward medical occurrence in a clinical study  participant, temporally  
associated with the use of study  intervention, whether or not considered related to the 
study  intervention.
    
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study intervention.
    NOTE: For purposes of AE definition, study  intervention (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether
investigational or marketed (including placebo, active comparator product, or run -in 
intervention) , manufactured by , licensed by , provided by , or distributed by  [CONTACT_88715] .
Events meeting the AE definition
    Any  abnormal la boratory  test results (hematology , clinical chemistry , or urinal ysis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the medical 
and scientific judgment of the investigator.
    Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency  and/or intensity  of the condition.
    New conditions detected or diagnosed after study  intervention admini stration even 
though it may  have been present before the start of the study .
    Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
    Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
interve ntion or a concomitant medication.
    For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical s ymptoms or abnormal test result. An overdose 
without any  associated clinical sy mptoms or abnormal laboratory  results is reported using 
the terminology  “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  80
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Events NOT meeting the AE d efinition
    Medical or surgical procedure (eg, endoscop y, appendectomy ): the condition that leads to 
the procedure is the AE.
    Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
    Anticipated day -to-day fluctuations of pre -existing di sease(s) or condition(s) present or 
detected at the start of the study  that do not worsen.
    Surgery  planned prior to informed consent to treat a pre -existing condition that has not 
worsened.
    
Refe r to Section 8.4.[ADDRESS_632135] medical occurrence that, at any dose:
a.   Results in death
b.   Is life-threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which h ypothetically  might have caused death, if it were m ore severe.
c.   Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_19357], regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observa tion. (Note: 
Hospi[INVESTIGATOR_19358] a pre -existing condition that has not 
worsened is not an SAE. )A pre -existing condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the pa rticipant’s 
medical history .
d.   Results in persistent or significant disability/incapacity
•The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
•This definition is not intended to include experiences o f relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  81
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
every day life functions but do not constitute a substantial disrupt ion.
e.   Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagnosis.
f.   Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_43193] 1 
of the other outcomes listed in the above definition. These events should usually  be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
10.3.3 Additional Events Reported
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.4 Recording AE and SAE
AE and SAE r ecording
    When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory , and diagnostics reports) related to 
the event.
    The investigator will record all relevant AE/SAE information on the AE 
CRFs /worksheets at each examination.
·    It is not acceptable for the inve stigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
    There may  be instances when copi[INVESTIGATOR_63475] b y 
the Sponsor. I n this case, all participant identifiers, with the exception of the participant  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  82
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
number, will be blinded on the copi[INVESTIGATOR_180580].
    The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of i ntensity /toxicity
    An event is defined as “serious ”when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of intensity  for each AE and SAE (and other 
reportable safet y event) by  [CONTACT_491492], version 2.[ADDRESS_632136] each change of grade 
recorded on the AE CRFs/worksheets.
-Grade 1 Mild event : Mild sy mptoms causing no or minimal interference with usual 
social and functional activities with intervention not indicated.
-Grade 2 Moderate event : Moderate s ymptoms caus ing greater than minimal 
interference with usual social and functional activities with intervention indicated.
-Grade 3 Severe event: Severe s ymptoms causing inability  to perform usual social and 
functional activities with intervention or hospi[INVESTIGATOR_491483].
-Grade 4 Potentiall y life -threatening event: Potentially  life-threatening s ymptoms 
causing inability  to perform basic self -care funtions with intervention indicated to 
prevent permanent impairment, persistent disability, or death.
-Grade 5 Death: De aths related to an AE.
Assessment of c ausality
•Did the Sponsor ’s product cause the AE?
•The determination of the likelihood that the Sponsor ’s product caused the AE will be 
provided b y an investigator who is a qualified physician. The investigator’s signed/ dated 
initials on the source document or worksheet that supports the causalit y noted on the AE 
form, ensures that a medically  qualified assessment of causalit y was done. This initialed 
document must be retained for the required regulatory  time frame. The c riteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the rela tionship between the 
Sponsor ’s product and the AE ; the greater the correlation with the components and  
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  83
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
their respective elements (in number and/or intensity ), the more likel y the Sponsor ’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actuall y exposed to the 
Sponsor ’s product such as: reliable history , acceptable compliance assessment (pi[INVESTIGATOR_9650], diary , etc.), expected pharmacologic effect, or measurement of 
drug/metabolite in bodil y specimen ?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor ’s product? I s the time of onset of the AE compatible 
with a drug -induced effect (applies to studies with investigational medicinal 
product)?
-Likely Cause: Is the AE not reasonabl y explained by  [CONTACT_63556], other drug(s)/vaccine(s), or other host or environmental factors.
-Dechallenge: Was the Sponsor ’s product discontinued or dose/exposure/frequency  
reduced?
◦If yes, did the AE resolve or improve?
◦If yes, this is a positive dechallenge.
◦If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability ; (2) the AE resolved/improved despi[INVESTIGATOR_55530] ’s 
product; (3) the stud y is a single -dose drug stud y; or (4) Sponsor ’s product(s) is/are 
only used 1 time.)
-Rechallenge: Was the participant re -exposed to the Sponsor ’s product in this study ?
◦If yes, did the AE recur or worsen?
◦If yes, this is a p ositive rechallenge.
◦If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability , or (2) the study  is a single -dose drug study; or (3) Sponsor ’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PL ANNED FOR AN AE THAT WAS SERI OUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370] ’S PRODUCT, OR I F RE -EXPOSURE 
TO THE SPONSOR ’S PRODUCT POSES ADDITIONAL POTENTIAL SI GNIFICANT 
RISK TO THE PARTI CIPANT THEN THE RECHALLENGE MUST BE APPROVED I N 
ADVANCE BY [CONTACT_63557], AND IF REQUI RED, THE 
IRB/IEC . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  84
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor ’s product or drug class 
pharmacology  or toxicology ?
•The assessment of relationship will be reported on the case report forms/worksheets b y 
an investigator who is a qualified phy sician according to his/her best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor ’s product relationship).
-Yes, there is a reasonable possibility  of Sponso r’s product relationship:
◦There is evidence of exposure to the Sponsor ’s product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor ’s product is 
reasonable. The AE is more likely  explained by  [CONTACT_1034] ’s product than by  
[CONTACT_5748].
-No, there is not a re asonable possibility  of Sponsor’ s product relationship:
◦Participant did not receive the Sponsor ’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor ’s product is not reasonable 
OR the AE is more likely explained by  [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
•There may  be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causalit y for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow -up report with the updated causality  assessment.
•The causality  assessment is 1 of the criteria used when determining regulatory  reporting 
requirements.
Follow -up of AE and SAE
    The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y Sponsor to 
elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, or 
consultation with other health care professionals. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  85
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
    New or updat ed information will be recorded in the CRF.
·    The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.5 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponsor
AE, SAE, and o ther reportable safety e vent reporting to Sponsor via electronic d ata 
collection t ool
    The primary  mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic s ystem is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
    The site will enter the SAE data into the electronic system as so on as it becomes 
available.
    After the stud y is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry  of new data or changes to existing data.
    If a site receives a report of a new SAE from a study participant or recei ves updated data 
on a previousl y reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
    Contacts for SAE reporting can be found in the Investigator Study  File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF
    If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
    In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
    Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.
    Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study  File Binder (or equivalent) . 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  86
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.4 Append ix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
Not applicable. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  87
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Nonchildbearing Potential (WONCBP)
Women in the following categories are considered WONCBP:
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medica l cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medica l examination, or medical history  interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
◦A high FSH level in the postmenopausal range may  be used to confirm a 
postmenopausal stat e in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_632137] discontinue HRT to 
allow confirmation of postmenopausal status before study  enrollment.
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below):
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  88
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
- Documented h ysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history  interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may  be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT . 
However, in the absence of [ADDRESS_632138]: MK-8591  89
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc,d
•IUSc,e
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an addit ional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s revie w of 
the participant’s medical records, medi cal examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Com bined (estrogen -and progestogen -containing) hormonal contraceptionc,d
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc,d
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone -only hormonal contraception where inhibition of ovulation is not the primary mode of action
•Male or female condom with or with out spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods)f
a   Contraceptive use by [CONTACT_491493] w omen should be consistent w ith local regulations regarding the use of 
contraceptive methods for participants of clinical studies.
b   Ty pi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
Note: The follow ing are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), w ithdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with fr iction ). 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  90
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.  Definitions
a.   Biomarker: A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body  responds to a treatment for a disease or condition .1
b   Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.   Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.   DNA: Deox yribonucleic acid.
e.   
RNA: Ribonucleic acid.
2.  Scope of Future Biomedical Research
The specime ns consented and/or collected in this study  as outlined in Section 8. 9will be 
used in various experiments to understand:
◦The biology  of how drugs/vaccines work
◦Biomarkers responsible for how a drug/vaccine enters and is removed b y the body
◦Other pathway s with which drugs/vaccines may  interact
◦The biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by  [CONTACT_63558].
3.  Summary of Procedures for Future Biomedical Researc h
a.   Participants for Enrollment
All participants enrolled in the clinical study  will be considered for enr ollment in future 
biomedical research. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  91
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
b.   Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study visit 
by [CONTACT_63559] d esignate. Informed consent for future biomedical 
research should be presented to the participants on the visit designated in the SoA. If 
delay ed, present consent at next possible Participant Visit. Consent forms signed b y the 
participant will be kept at the clinical study  site under secure storage for regulatory  
reasons.
A template of each stud y site’s approved informed consent will be stored in the Sponsor’s 
clinical document repository .
c.   eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical r esearch will be captured in 
the eCRFs . Any specimens for which such an informed consent cannot be verified will be 
destroy ed.
d.   Future Biomedical Research Specimen (s)
Collection of specimens for future biomedical r esearch will be performed as outlined in 
the SoA. I n general, if additional blood specimens ar e being collected for future 
biomedical r esearch, these will usually  be obtained at a time when the participant is 
having blood drawn for other study  purposes.
4.  Confidential Participant Information for Future Biomedical Research
In order to optimize the resea rch that can be conducted with future biomedical r esearch 
specimens, it is critical to link participant s'clinical information with future test results. In 
fact,little or no research can be conducted without connecting the clinical study  data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history  and intervention outcomes are 
critical to understanding clinical context of anal ytical results.
To maintain privacy  of information collect ed from specimens obtained for future 
biomedical r esearch, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below.
At the clinical study  site, unique codes will be placed on the future biomedical r esearch 
specimens. This code is a random number which does not contain any personally 
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the study  site. No personal identifiers will 
appear on the specimen tube. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  92
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632139] party  (eg, a university  investigator) designate d by 
[CONTACT_1034]. The investigator conducting the anal ysis will follow the Sponsor’s privacy 
and confidentialit y requirements. An y contracted third part y anal yses will conform to the 
specific scope o f anal ysis outlined in future biomedical research protocol and consent . 
Future biomedical r esearch specimens remaining with the third party  after specific 
analysis is performed will be reported to the Sponsor.
6.  Withdrawal From Future Biomedical Research
Participants may  withdraw their consent for future biome dical r esearch and ask that thei r 
biospecimens not be used for future biomedical r esearch. Participants may withdraw 
consent at an y time b y contact[CONTACT_491494]. If medical records 
for the main study  are still available, the investigator will contact [CONTACT_111972] ([EMAIL_1250]). Subsequently, the 
participant's specimens will be flagged in the biorepository and restricted to main study 
use only . If specimens were collected from study participants specifically  for future 
biomedical r esearch, these specimens will be removed from the biorepository and 
destroy ed. Documentation will be sent to the investigator confirming withdrawal and/or 
destruction, if applicable. I t is the responsibility  of the investigator to inform the 
participant of completion of the withdrawal and/or destruction, if applicable. Any 
analyses in progress at the time of request for withdrawal/destruction or alread y 
performed prior to the request being recei ved b y the Sponsor will continue to be used as 
part of the overall research study  data and results. No new analy ses would be generated 
after the request is received.
In the event that the medical records for the main study  are no longer available (eg, if t he 
investigator is no longer required b y regulatory authorities to retain the main study 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situation, 
the request for withdrawal of consent and/or destruction cannot be processed.
7.  Retention of Specimens
Future biomedical r esearch specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_632140]: MK-8591  93
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632141] results are accessible only  to the 
authorized Sponsor representatives and the designated study administrator research 
personnel and/or collaborators. Database user authentication is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9.  Reporting of Future Biomedical Research Data to Participants
No information obta ined from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may  publish results, present 
results in national meetings, and make results accessible on a public website in order to 
rapi[INVESTIGATOR_252314]. Participants will not be 
identified by  [CONTACT_63561].
10. Future Biomedical Research Study Population
Every  effort will be made to recruit al l participants diagnosed and treated o n Sponsor 
clinical studies for f uture biomedical r esearch.
11.Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been mini mized and are 
described in the f uture biomedical r esearch informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy  concerns. Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentia lity. In this highl y unlikely  situation, there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e mailed directly  to 
clinical.specimen.management@merc k.com. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  94
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
13.References
1.  National Cancer Institute [I nternet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.  International Council on Harmoni sation [Internet] : E15 : Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy -
single/article/definitions -for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -
genomic -data-and-sample -cod.html 
3.  Industry  Pharmacogenomics Working Group [Internet]: Understanding the I ntent, Scope 
and Public Health Benefits of Exploratory  Biomarker Research: A Guide for I RBs/IECs 
and Investigational Site Staff. Available at http://i -pwg.org/ 
4.  Industry  Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for I RBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/ 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  95
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.7 Appendix 7: Country -specific Requirements
Not ap plicable. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  96
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.8 Appendix 8: Blood Volume Table
Participants Pre-studyTreatm ent 
PeriodsTotal 
CollectionsmL Per 
Collection Total mL/ Test
Laboratory Safety Tests
      Chemistrya
      Hematology1
12
23
38.5
425.5
12
Blood for Planned Genetic 
Analysis1 1 8.5 8.5
HIV Antigen/Antibody & 
/Hepatitis Screen1b1 8.5 8.5
Blood for syphilis screen 1 1 5 5
Blood for methadone 21 21 6 126
Blood for ISL 13 13 4 52
Total Blood Volume per Participant: 237.5 mLc
aIncludes serum FSH (WONCBP only) and serum β -hCG (WOCBP only).
b  Hepatitis screen conducted at pre- study visit only.
cIf additional pharmacokinetic/pharmacodynamic and/or safety analysis is necessary, additional blood (up 
to 50 mL) may be obtained. Note : never to exceed [ADDRESS_632142]: MK-8591  97
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.9 Appendix 9: 12-Lead Electrocardiogram Abnormality Criteria
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteria Potentially Significant 
Postrandomization Findings 
(clarification on action to take)
RHYTHM
Sinus Tachycardia 110 bpmHR >110 bpm and HR increase of 
≥25bpm from baseline
Sinus Bradycardia <40 bpmHR <40 bpm and HR decrease of 
≥5bpm from baseline
Sinus Pause/Arrest >2.0 seconds >2.0 seconds
Atrial Premature C omplex 1 beat 3 beats
Ventricular Prema ture C omplex All 3 beats
Ectopic Atrial Rhythm None None
Junctional RhythmJunctional Rhythm with HR < 40 
bpmJunctional Rhythm with HR < 40 
bpm
Idioventricular Rhythm All All
Atrial Fibrillation All All
Atrial Flutter All All
Supraventricular Tachycardia All All
Ventricular Tachycardia All All
AXIS
Left Axis DeviationRBBB W ith Left Anterior 
Hem iblock (LAHB)New  Onset LAHB
Right Axis DeviationRBBB W ith Left Posterior 
Hem iblock (LPHB)New  Onset LPHB
CONDUCTION
1st Degree A V Block PR  230 msPR  230 ms   + Increase of 15 ms; 
or PR Increase of > 25%
2nd Degree AV Block Mobitz Type II Mobitz Type II
3rd Degree A V Block All All
LBBB All All
RBBBRBBB With LAHB/LPHB as 
Defined A boveNew  Onset RBBB (N ot Including 
Rate-related)
Incomplete Right BBB 
(ICRBBB) (QRS <120 ms)No E xclusion Nothing
Short PR/ Preexcitation 
SyndromeDelta W ave + PR <[ADDRESS_632143] + PR <120 ms
Other Intra -Ventricular 
Conduction DelayQRS 130 ms QRS 130 ms + I ncrease of 10 ms
QTc (B or F)
Male QTc 450msQTc 500 ms or I ncrease of 60 ms 
From  Baseline
Female QTc 470msQTc 500 ms or I ncrease of [ADDRESS_632144]: MK-8591  98
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
12-Lead Electrocardiogram Abnormality Criteria 
Screen Failure Criteria Potentially Significant 
Postrandomization Findings 
(clarification on action to take)
HYPERTROPHY
Atrial AbnormalitiesDefinite Evidence of P Mitrale or 
P Pulmo naleDefinite Evidence of P Mitrale or P 
Pulmonale
Ventricular A bnormalitiesVoltage Criteria for LVH P lus 
Strain PatternVoltage Criteria  for LVH P lus 
Strain Pattern
MYOCARDIAL INFARCTION
Acute or Recent All All
Old All All
ST/T MORPHOLOGY
ST Elevation S uggestive of 
Myocardial Injury In [ADDRESS_632145] -T Changes 
(In 2 or More L eads)No exclusion In 2 or more contiguous leads
PACEMAKER All All
Baseline is defined as Predose Day 1 ; ms=milliseconds, mm=millimeter 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  99
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.10 Appendix 10: Algorithm for Assessing Out of Range Laboratory Values
For all laboratory  values obtained at prestud y (screening) visit and/or predose evaluation:
A.If all protocol -specified laboratory  values are normal, the participant may  enter the stud y.
B.If a protocol specified laboratory  value is outside of the parameter(s) outlined in the 
inclusion/exclusion criteria (including a repeat if performed), the participant will be 
excluded from the study .
C.If ≥1 protocol -specified laboratory  value not specified in the inclusion/exclusion criteria 
is outside the normal range, the following choices are available:
1. The participant may  be excluded from the study ;
2. The participant may  be included in the study  if the abnormal value(s) is NCS 
(the investigator must annotate the laboratory  value “NCS” on the laboratory  
safet y test source d ocument).
3. The participant may  be included in the study  if the abnormalit y is consistent 
with a pre -existing medical condition which is not excluded per protocol (eg, 
elevated eosinophil count in a participant with asthma or seasonal allergies),
the medical condition should be annotated on the laboratory  report .
OR
4. The abnormal test may  be repeated (refer items a. and b. below for 
continuation of algorithm for repeated values).
a.   If the repeat test value is within the normal range, the participant may  
enter the stud y.
b.   If the repeat test value is still abnormal, the study investigator will 
evaluate the potential participant with a complete history  and ph ysical 
examination, looking especiall y for diseases that could result in the 
abno rmal laboratory  value in question. If such diseases can be ruled out, 
and if the abnormal laboratory  value is not clinically  relevant, then the 
participant may  enter the study .
D.If there is an y clinical uncertaint y regarding the significance of an abnorm al value, the 
participant will be excluded from the stud y. 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  100
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
10.11 Appendix 11: Abbreviations
Abbreviation Expanded Term
ADA Adenosine deaminase
AE adverse event 
APaT All-Participants -as-Treated
AR adverse reaction
ART anti-retroviral therapy
BDS blood drug screen
β-hCG β-human chorionic gonadotropin
BID twice daily
BMI body  mass index
BP blood pressure
CG Cockcroft -Gault
CNS central nervous system 
CKD -EPI [INVESTIGATOR_491484]-induced liver injury
DMC Data Monitoring Committee 
DNA deoxyribonucleic acid 
DOR doravarine
DTG dolutegravir
ECG electrocardiogram 
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection 
eGFR estimated glomerular filtratio n rate
ELISA enzyme-linked immunosorbent assay
EMA European Medicines Agency
EOC Executive Oversight Committee 
FSH follicle stimulating hormone 
GCP Good Clinical Practice 
HbsAg Hepatitis B surface antigen
HBV Hepatit is B virus
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International C ouncilon Harmoni sation
IEC Independent Ethics Committee
IND Investigational New Drug 
IRB Institutional Review Board
ISL Islatravir
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
LNG/EE Levonorgestrel/ethinyl estradiol 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  101
PROTOCOL/AMENDMENT N O.:029-[ADDRESS_632146] drugs
QM Once monthly
QW Once a week
QP2 department of quantitative pharmacology and pharmacometrics
RNA ribonucleic acid
SAE serious adverse event 
SAP Statistical Analysis Plan
SoA schedule of activities
S[LOCATION_003]R suspected unexpected serious adverse reaction
TDF Tenofovir disoproxil fumarate
TP triphosphate
UDS urine drug screen
V volume of distribution
VS vital sign
WBC white blood cell
WOCBP woman/ women of childbearing potential 
WONCBP Wom an/women of nonchildbearing potential 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  102
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
11 REFERENCES
[Centers for Disease Control 
and Prevention 2015]Centers for Disease Control and Prevention. 
Factors increasing the risk of acquiring or 
transmitting HIV. Washington (DC): 
Department of Health and Human Services 
(HHS); 2015 Dec. 4 p.[05KS5C]
[Centers for Disease Control 
and Prevention 2020]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS). 
Diagnoses of HIV infection in the United 
States and dependent areas, 2018: 
diagnoses: diagnoses of HIV infection; 
[cited 2020 Aug 24]; [about 19 screens]. 
Available from: 
https://www.cdc.gov/hiv/library /report s/hiv -
surveillance/vol -31/content/diagnoses.html.[05KS5B]
[Centers for Disease Control 
and Prevention 2020]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS). PrEP; 
[cited 2020 Aug 24]; [about 11 screens]. 
Available from: 
https://www.cdc.gov/hiv/basics/prep.html.[05KS97]
[Centers for Disease Control 
and Prevention 2020]Centers for Disease Control and Prevention 
[Internet]. Washington (DC): Department of 
Health and Human Services (HHS).
Injection drug use and HIV risk; [cited 2020 
Aug 24]; [about 5 screens]. Available from: 
https://www.cdc.gov/hiv/risk/idu.html.[05KS5D]
[Eap, C. B., et al 2002] Eap CB, Buclin T, Baumann P. 
Interindividual Variability  of the Clinical 
Pharmacokinetics of Methadone: 
Implications for the Treatment of Opi[INVESTIGATOR_413545]. Clin Pharmacokinet 
2002;41(14):1153 -93.[03RRK3]
[Joint United Nations 
Programme on HIV/AIDS 
2020]Joint United Nations Programme on 
HIV/AIDS. Fact sheet: global HIV statistics. 
Geneva (Swit zerland): Joint United Nations 
Programme on HIV/AIDS (UNAIDS); 
2020. 7 p.[05KS98] 
  05KTY6
05KTY6
07ZM3G
PRODUCT: MK-8591  103
PROTOCOL/AMENDMENT N O.:029-00 
MK-8591 -029-00FINAL PROTOCOL 28-AUG -2020
[Maremmani, I ., et al 2005] Maremmani I, Pacini M, Cesaroni C, 
Lovrecic M, Perugi G, Tagliamonte A. QTc 
interval prolongation in patients on long -
term methadone maintenance therap y. Eur 
Addict Res. 2005;11:44- 9.[05KS80]
[McCance -Katz, E. F., et al 
1998]McCance -Katz EF, Rainey  PM, Jatlow P, 
Friedland G. Methadone effects on 
zidovudine disposition (AIDS Clinical 
Trials Group 262). J Acquir I mmune Defic 
Syndr Hum Retrovirol. 1998 Aug 
15;18(5):435 -43.[04625Z]
[Rainey , P. M., et al 2000] Rainey  PM, Friedland G, McCance -Katz F, 
Andrews L, Mitchell SM, Charles C, et al. 
Interaction of methadone with didanosine 
and stavudine. JAI DS 2000;24(3):241 -8.[03QQTP]
[Schwart z, E. L ., et al 1992] Schwartz EL , Brechbuhl AB, Kahl P, Miller 
MA, Selwy n PA, Friedland GH. 
Pharmacokinetic interactions of zidovudine 
and methadone in intravenous drug- using 
patients with HIV infection. J Acquir 
Immune Defic S yndr. 1992;5(6):619- 26.[046274]
[U.S. Prescribing Information 
2019]U.S. Prescribing Information: DOL OPHINE 
(methadone h ydrochloride) tablets, for oral 
use: Oct 2019.[05KV5B]
[Volpe, D. A., et al 2018] Volpe DA, Xu Y, Sahajwalla CG, Younis 
IR, Patel V. Methadone metabolism and 
drug- drug interactions: in vitro and in vivo 
literature review. J Pharm Sci. 
2018;107:2983- 91.[05KS82]
[Wesson, D. R. 2003] Wesson DR, L ing W. The Clinical Opi[INVESTIGATOR_2430] (COWS). J Psy choactive 
Drugs. 2003 Apr -Jun;35(2):253- 9.[04628F] 
  05KTY6
05KTY6
07ZM3G